

TRADE SECRET

Study Title

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

Laboratory Project ID: DuPont-4292

AUTHOR: David P. Kelly, B.S.

STUDY COMPLETED ON: October 6, 2000

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Toxicology and Industrial Medicine
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050

WORK REQUEST NUMBER: [REDACTED]

SERVICE CODE NUMBER: [REDACTED]

**CLINICAL PATHOLOGY
NUMBER:** [REDACTED]


GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study was conducted in compliance with U.S. EPA TSCA (40 CFR part 792) Good Laboratory Practice Standards except for the items documented below. None of the items listed impact the validity of the study.

1. The test substance was characterized by the sponsor prior to the initiation of this study and a report was supplied, however, records of the characterization are not available. Although the characterization was not performed under Good Laboratory Practice Standards, based on the familiarity with the laboratory and the techniques used, the data is considered sufficient for the purposes of this study.
2. Prior to the daily experiments, samples of the test compound were transferred to holding containers. These intermediate containers were used for convenience in transferring the test compound into syringes that were used in metering the test chemical into the atmosphere generation system. The intermediate containers were not labeled in compliance with Good Laboratory Practice Standards. In addition, the weights of the test substance were recorded on sample containers and later transferred to the study notebook and labels were discarded.

Submitter / Sponsor: E. I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.

Study Director: _____


David P. Kelly, B.S.
Research Scientist

Date

6-OCT-2000

DuPont Registration
Representative: _____

Date

QUALITY ASSURANCE STATEMENT

Haskell Sample Number(s):

24267

Dates of Inspections:

Conduct: May 2, 4, 17, 2000


Records, Reports: September 13-15, 18-21, 2000

Dates Findings Reported to:

Study Director: September 21, 2000

Management: October 6, 2000

Reported by:



Joseph C. Hamill
Senior Quality Assurance Auditor


06 - Oct. 2000

Date

CERTIFICATION

We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.

**Clinical Pathology
Evaluations Reported by:**



Nancy E. Everds, D.V.M.
Diplomate A.C.V.P.
Principal Research Scientist

6 Oct 2000

Date

**Anatomic Pathology
Evaluations Reported by:**




Steven R. Frame, D.V.M., Ph.D.
Diplomate A.C.V.P.
Director

6 Oct 2000

Date

**Anatomic
Pathology Evaluations
Peer Review by:**




G. Tracy Makovec, D.V.M.
Diplomate A.C.V.P.
Senior Research Scientist

6 Oct 2000

Date

Approved by:




Scott E. Loveless, Ph.D.
Director

6 Oct 2000

Date

Issued by Study Director:



David P. Kelly, B.S.
Research Scientist

6 Oct 2000

Date

TABLE OF CONTENTS

	Page
GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT	2
QUALITY ASSURANCE STATEMENT	3
CERTIFICATION	4
LIST OF TABLES	7
LIST OF FIGURES	7
LIST OF APPENDICES	8
STUDY INFORMATION	9
STUDY PERSONNEL.....	10
SUMMARY	11
INTRODUCTION.....	12
MATERIALS AND METHODS	12
A. Test Substance	12
B. Animals	12
C. Animal Husbandry	12
1. Temporary Animal Identification and Quarantine	12
2. Housing	13
3. Animal Room Environment.....	13
4. Animal Selection and Permanent Identification	13
5. Feed and Water.....	13
6. Health Monitoring Program.....	13
D. Study Design	14
E. Inhalation Exposure System.....	14
1. Atmosphere Generation.....	14
2. Chamber Construction and Design.....	14
3. Exposure Mode	15
F. Characterization of Chamber Atmosphere.....	15
1. Test Substance Sampling and Analysis	15
2. Environmental Monitoring	15
G. Body Weights and Clinical Observations	15
H. Clinical Pathology Evaluations	16
1. Hematology	16
2. Coagulation Parameters.....	16
3. Serum Chemistry	16
4. Urinalysis.....	17
I. Anatomic Pathology Evaluations.....	17
J. Statistical Analyses	18

TABLE OF CONTENTS (Continued)

	Page
RESULTS AND DISCUSSION	20
In-Life Animal Measurements.....	20
A. Chamber Atmosphere Analysis of H-24267	20
B. Body Weights and Clinical Observations	20
Clinical Pathology Evaluations.....	21
A. Hematology/Coagulation	21
B. Serum Chemistry.....	21
C. Urinalysis	22
D. Conclusions.....	23
Anatomic Pathology Evaluations.....	23
A. Organ Weights	23
B. Gross Observations	23
C. Microscopic Findings.....	24
D. Conclusions.....	24
CONCLUSIONS	25
RECORDS AND SAMPLE STORAGE	25
REFERENCES.....	26
TABLES.....	27
FIGURES.....	73
APPENDICES	76

LIST OF TABLES

	Page
1. CHAMBER CONCENTRATIONS OF H-24267	31
2. PARTICLE SIZE DISTRIBUTION OF H-24267	31
3. CHAMBER ENVIRONMENTAL CONDITIONS	31
4. MEAN BODY WEIGHTS OF MALE RATS	32
5. MEAN BODY WEIGHT GAINS OF MALE RATS	34
6. SUMMARY OF CLINICAL OBSERVATIONS IN MALE RATS AT WEIGHING	36
7. SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS	37
8. SUMMARY OF COAGULATION VALUES FOR MALE RATS	42
9. SUMMARY OF SERUM CHEMISTRY VALUES FOR MALE RATS	43
10. SUMMARY OF URINALYSIS VALUES FOR MALE RATS	46
11. MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS DAY 11 SACRIFICE	47
12. MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS DAY 25 SACRIFICE	49
13. INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS DAY 11 SACRIFICE	51
14. INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS DAY 25 SACRIFICE	56
15. INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS DAY 11 SACRIFICE	60
16. INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS DAY 25 SACRIFICE	70

LIST OF FIGURES

	Page
1. SCHEMATIC OF EXPOSURE SYSTEM	74
2. MEAN BODY WEIGHTS OF MALE RATS	75

LIST OF APPENDICES

	Page
A. DAILY ATMOSPHERIC ANALYSES	77
B. DAILY ENVIRONMENTAL CONDITIONS	81
C. INDIVIDUAL BODY WEIGHTS	85
D. INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY RECORDS	90
E. INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA	95
F. INDIVIDUAL ANIMAL FINAL BODY AND ORGAN WEIGHTS.....	135
G. INDIVIDUAL ANIMAL PATHOLOGY DATA.....	140

STUDY INFORMATION

Substance Tested: [REDACTED]

Synonyms/Codes: • H-24267

[REDACTED]

Haskell Number: 24267

MSDS Reference Number: [REDACTED]

Composition: [REDACTED]

Known Impurities: [REDACTED]

Physical Characteristics: [REDACTED]

Stability: The test substance appeared to be stable under the conditions of the study; no evidence of instability was observed.

Sponsor: E. I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.

Study Initiated/Completed: May 4, 2000 / (see report cover page)

In-Life Initiated/Completed: May 8, 2000 / June 2, 2000

STUDY PERSONNEL

Study Director: David P. Kelly, B.S.

Management: Scott E. Loveless, Ph.D.

Nancy C. Chromey, Ph.D.

Primary Technician: Thomas A. Kegelman, A.A.

Clinical Pathologist: Nancy E. Everds, D.V.M.

Management: Steven R. Frame, D.V.M., Ph.D.

Pathologist: Steven R. Frame, D.V.M., Ph.D.

Management: Steven R. Frame, D.V.M., Ph.D.

Robert W. Rickard, Ph.D., D.A.B.T.

Peer Review Pathologist: G. Tracy Makovec, D.V.M.

Toxicology Report Preparation: Maryanne M. Wilford, B.A.

Laboratory Veterinarian: Wanda L. West, D.V.M., A.C.L.A.M.

SUMMARY

Groups of 10 male Crl:CD(SD)IGS BR rats were exposed for 6 hours/day, for a total of 9 exposures over a 2-week period to design concentrations of 25, 125, or 600 mg/m³ (actual mean concentrations were 23, 110, and 600 mg/m³) of H-24267 aerosol. The mass median aerodynamic equivalent diameter of the aerosols ranged from 2.6 to 4.2 μ m. A control group of 10 male rats was exposed simultaneously to houseline air. At the end of the exposure period, blood and urine samples were collected for clinical analyses, and 5 rats per group were sacrificed for pathologic examination. After a 2-week recovery period, the surviving rats were also given clinical and pathologic examinations.

During the exposure period a dose-related body weight depression occurred primarily in the 125 and 600 mg/m³ groups and all 3 test groups gained less weight than the controls. The H-24267 exposed rats resumed a normal weight gain rate during the recovery period.

Clinical pathology evaluations at both evaluation times showed no toxicologically significant changes in hematology, clinical chemistry, or urinalysis parameters, including urinary fluoride.

Weight analysis of the major organs showed no effects attributable to the test compound.

Histological findings were confined to the respiratory tract; there were no significant findings in any other evaluated organs. Minimal, dose-related histologic effects attributable to the test compound were detected in the respiratory tract of all treated groups at the end of the 2-week exposure period. The effects were consistent with minimal irritation and were slightly more apparent with increasing dose. These effects occurred throughout the respiratory tract, including the nose, larynx, and lung. In the lung, inflammation was characterized by mild thickening of alveolar duct bifurcations and adjacent alveolar septa due to mononuclear inflammatory cell infiltration. Slight hypertrophy of terminal bronchiolar epithelium was also present in association with the centriacinar inflammatory response. In the larynx, minimal squamous metaplasia was present in all treated groups. Necrosis of cartilage overlying the laryngeal saccule was present in 1 rat in the 600 mg/m group. In the nose, hypertrophy of goblet cells was present in all treated groups and was most apparent in the mucosa of the pharyngeal duct.

Following an approximate 2-week recovery period, respiratory tract lesions were essentially reversible. Single occurrences of focal, very slight thickening of alveolar duct septa occurred in the 125 and 600 mg/m³ recovery groups. In addition, focal residual cartilage necrosis in the larynx occurred in 2/5 rats in the 600 mg/m³ recovery group.

Based on the finding of minimal respiratory tract inflammation observed in all exposed groups, including the lowest concentration tested, 25 mg/m³, a no-observed-adverse-effect-level (NOAEL) was not determined for repeated aerosol exposures to H-24267 in rats.

INTRODUCTION

The purpose of this 2-week inhalation study was to investigate the effects of repeated inhalation exposure in rats to high concentrations of H-24267. Inhalation is an expected route of human exposure. The data will be used to provide information for safe handling of the test substance.

The 4-hour approximate lethal concentration (ALC) in rats for this compound was 3.9 mg/L; no rats died after exposure to 2.3 mg/L (DuPont HL-1997-00273). Prior to the present study, a rangefinding experiment was conducted in groups of rats exposed for approximately 6 hours/day for 3 days to a mean concentration of approximately 790 mg/m³ of the test compound. During 1 exposure there was a reduced response to an alerting stimulus observed. After exposure, lung noise and weight loss were observed. These effects were reversible within 2 days. In another experiment weight loss was observed in rats exposed for 3 days to a mean concentration of 31 mg/m³ with excursions as high as 69 mg/m³; the rats resumed a normal weight gain on the day after the last exposure. A group of rats exposed for 1 day to 25 mg/m³ showed no effects.

MATERIALS AND METHODS

A. Test Substance

The test substance, H-24267, was supplied by the sponsor as a [REDACTED] A batch analysis was provided by the sponsor. The test substance was assumed to be stable throughout the exposure phase of the study; no evidence of instability was observed.

B. Animals

Male Crl:CD[®](SD)IGS BR rats were received from Charles River Laboratories, Inc., Raleigh, North Carolina. The rats were approximately 7 weeks old on the day of arrival.

Rats have historically been used in safety evaluation studies for inhalation toxicity testing. The Crl:CD[®](SD)IGS BR rat was selected based on consistently acceptable health status and on extensive experience with the strain at Haskell Laboratory.

C. Animal Husbandry

1. Temporary Animal Identification and Quarantine

Upon arrival, each rat was assigned a temporary, 1- to 2-digit identification number, which was recorded on a card affixed to the cage. Rats were quarantined for 6 days prior to test initiation. During the quarantine period rats were weighed and observed 3 times for clinical signs of disease.

2. Housing

Rats were housed either singly or in pairs in suspended, stainless steel, wire-mesh cages.

3. Animal Room Environment

Animal rooms were maintained on a timer-controlled, 12-hour light/12-hour dark cycle. Environmental conditions of the rooms were targeted to be within a temperature range of $23 \pm 2^{\circ}\text{C}$ and a relative humidity range of $50 \pm 10\%$. Excursions outside of these ranges were of insufficient magnitude and/or duration to have adversely affected the validity of the study.

4. Animal Selection and Permanent Identification

Prior to the end of the quarantine period, rats were assigned to 4 groups of 10 male rats each. Rats were divided into groups with the aid of a computerized, stratified, randomization program, so that mean body weights for each group were similar. Rats were approximately 8 weeks old and weighed between 257 and 333 grams at the start of the exposures.

Upon grouping, each rat was assigned a unique 6-digit animal number. Following grouping, a 1- to 2-digit identification number was tattooed onto the tail of each rat. Both numbers were recorded on a card affixed to the cage.

5. Feed and Water

Except during exposure, tap water was available *ad libitum*. PMI Nutrition International, Inc. Certified Rodent LabDiet[®] 5002 was available *ad libitum* except during exposure and fasting periods prior to necropsy.

6. Health Monitoring Program

As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to assure that contaminant levels are below those that would be expected to impact the scientific integrity of the study:

- Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants.
- Feed samples are analyzed for total bacterial, spore and fungal counts.
- Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers.

Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study.

The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian.

D. Study Design

Four groups of 10 male rats each were exposed to concentrations of H-24267 targeted to 0, 25, 125, or 600 mg/m³. Rats were exposed nose-only for 6 hours per day for a total of 9 exposures. On the day of the last exposure, collection of an overnight urine specimen was initiated for each rat. On the day following the last exposure, blood samples were collected for clinical analyses, and 5 rats per group were sacrificed for anatomic pathology examination. All remaining rats were allowed to recover for a 14-day period. At the end of the recovery period, blood and urine samples were collected for clinical analyses, and all surviving rats were sacrificed for anatomic pathology examination.

All rats were weighed and individually observed for clinical signs of toxicity throughout the exposure period. Group clinical signs were observed during each exposure. In addition, the alerting response to an auditory stimulus was checked during each exposure. After each exposure, rats were checked for the alerting response to an auditory stimulus prior to removal from chambers and were observed for clinical signs immediately after they were returned to their cages. Surviving rats were weighed and individually observed for clinical signs of toxicity throughout the recovery period.

E. Inhalation Exposure System (Figure 1)

1. Atmosphere Generation

Chamber atmospheres were generated by nebulization of H-24267 in air with a Spraying Systems nebulizer. The test substance was metered into the nebulizer with a Harvard Model 22 syringe drive. The syringe containing the test substance was heated (as high as 60°C) to facilitate liquid spraying. Filtered houseline air, introduced at the nebulizer, atomized the test substance and carried the aerosol into the exposure chamber. Dilution air was added to the chamber turret so that the total airflow to each chamber was 30 liters per minute. A baffle placed at the bottom of the chamber turret was used to promote uniform aerosol distribution throughout the chamber. Varying the test substance feed rate to the aerosol generator controlled chamber concentrations of H-24267.

Test atmospheres were exhausted through a dry-ice cold trap and an MSA filter prior to discharge into the fume hood.

2. Chamber Construction and Design

The exposure chamber was constructed of stainless steel and glass (NYU style) with a nominal internal of 150 liters. A tangential air feed on the chamber promoted uniform chamber distribution of the test atmosphere.

3. Exposure Mode

During exposure, rats were individually restrained in stainless steel cylinders with conical nose pieces. The restrainers were inserted into the polymethylmethacrylate faceplate of the exposure chamber so that only the nose of each rat extended into the chamber.

F. Characterization of Chamber Atmosphere

1. Test Substance Sampling and Analysis

The atmospheric concentration of H-24267 was determined at approximately 60-minute intervals by gravimetric analysis of the test chambers. The control chamber was sampled once daily. Known volumes of chamber atmosphere were drawn from the breathing zone of the rats through 25 mm filter cassettes that contained preweighed Gelman glass fiber (Type A/E) filters. The filters were weighed on a Cahn Model C-26 Electrobalance[®]. The atmospheric concentrations of H-24267 were calculated from the difference in the pre- and post-sampling filter weights.

An air sample was taken from each exposure chamber^a once per week to determine the particle size distribution (mass median aerodynamic diameter and geometric standard deviation) using a Sierra[®] Series 210 cyclone preseparator/cascade impactor and Sierra[®] Series 110 Constant Flow Air Sampler.⁽¹⁾

2. Environmental Monitoring

Chamber airflow was set at the beginning of each exposure to achieve at least 12 air changes per hour. The airflow was monitored continually with a calibrated Brooks model 1355 Sho-Rate Rotometer and recorded initially and whenever changes were made. Chamber temperature was targeted at $22 \pm 2^\circ\text{C}$. The temperature was monitored continually with an Omega model DP41-TC Thermocouple Thermometer and recorded 3 times during each exposure. Chamber relative humidity was targeted at $50 \pm 10\%$. The relative humidity was measured with an Omega model RH5100C Digital Psychrometer and recorded twice during each exposure. Chamber oxygen concentration was targeted to at least 19%. The oxygen concentration was measured with a Biosystems model 3100R Oxygen Analyzer and recorded twice during each exposure.

G. Body Weights and Clinical Observations

During the exposure phase of the study, all rats were weighed daily and individually observed for clinical signs of toxicity before and after each exposure. Group clinical observations were made during exposures. In addition, rats were checked for an alerting response to an auditory stimulus 3 times during each exposure and after each exposure. During the recovery period, all remaining rats were weighed and individually observed daily.

a Particle size samples were not taken from the control chamber.

H. Clinical Pathology Evaluations

A clinical pathology evaluation was conducted on all rats after the last exposure and from all remaining rats on the last day of recovery. The day before collection of blood samples for the clinical pathology evaluation, the rats were placed in metabolism cages. These rats were fasted overnight and urine was collected from each rat. Blood samples for hematology and clinical chemistry measurements were collected from the orbital sinus of each rat while the rat was under light carbon dioxide anesthesia. Blood samples for coagulation parameters and fluoride analysis were collected under carbon dioxide immobilization from the abdominal *vena cava* at sacrifice. Blood samples were evaluated for quality by visual examination prior to analysis.

1. Hematology

The following hematology parameters were determined:

red blood cell count	absolute reticulocyte count
hemoglobin	white blood cell count
hematocrit	absolute differential white blood cell count
mean corpuscular volume	percent differential white blood cell count
mean corpuscular hemoglobin	platelet count
mean corpuscular hemoglobin concentration	microscopic blood smear examination
red cell distribution width	

Complete blood counts were determined on a Bayer® (Technicon®) H-1E hematology analyzer, calculated within the Xybion® data collection system using the hematology analyzer's results, or determined from microscopic evaluation of the blood smear. Wright-stained blood smears from all rats were examined microscopically for confirmation of automated results and evaluation of cellular morphology. Reticulocyte counts were determined on a Sysmex® R-3000. New methylene blue-stained blood smears were prepared from all hematology samples but were not needed for evaluation.

2. Coagulation Parameters

The following coagulation parameters were determined:

prothrombin time
activated partial thromboplastin time

Coagulation times were determined on a Sysmex® CA-1000.

3. Serum Chemistry

The following serum chemistry parameters were determined:

aspartate aminotransferase	total protein
alanine aminotransferase	albumin
sorbitol dehydrogenase	globulin

alkaline phosphatase	calcium
total bilirubin	inorganic phosphorus
urea nitrogen	sodium
creatinine	potassium
cholesterol	chloride
triglycerides	fluoride ^b
glucose	

Clinical chemistry parameters were measured on a Roche Diagnostics (BMC)/Hitachi® 717 clinical chemistry analyzer or calculated using results of chemistry tests within the Xybion® data collection system.

4. Urinalysis

The following urinalysis parameters were determined:

quality	glucose
color	ketone
transparency	bilirubin
volume	blood
osmolality	urobilinogen
specific gravity	fluoride ^c
pH	microscopic urine examination
protein	

Urine volume, color and transparency were evaluated visually. All other urine parameters were semi-quantitatively measured on a Bayer Clinitek® Atlas™ Automated Urine Chemistry, utilizing Ames Multistix® chemistry dipsticks. Sediments from all urine specimens were evaluated microscopically.

I. Anatomic Pathology Evaluations

After the last exposure, 5 rats per group were euthanized by carbon dioxide anesthesia and exsanguination and given gross and histopathology evaluations. On the last day of the recovery period, the remaining rats of each group were similarly sacrificed and evaluated.

All rats on study were given a complete gross examination and representative samples of the following tissues were saved at necropsy:

Hematopoietic System	- bone marrow (femur and sternum), mesenteric lymph nodes, spleen, thymus
Circulatory System	- heart
Respiratory System	- trachea, lungs, nose, larynx, pharynx

b Fluoride determination was analyzed from plasma with EDTA added.

c Fluoride determination was analyzed from urine with EDTA added.

Digestive System	- esophagus, stomach, liver, pancreas (exocrine and islets), small intestine (duodenum, jejunum, and ileum), large intestine (cecum, colon, and rectum)
Urinary System	- kidneys, urinary bladder
Endocrine System	- thyroid gland (cortex and medulla), parathyroid glands, adrenal glands,
Reproductive System	- prostate, testes, epididymides, seminal vesicles
Nervous System	- brain (cerebrum, midbrain, cerebellum, medulla/pons), spinal cord (cervical, thoracic, lumbar), sciatic nerve
Other	- eyes and selected gross lesions

Liver, kidneys, lungs, brain, and testes from rats sacrificed by design at the end of the exposure and recovery periods were weighed wet at necropsy.

Gross lesions which were diagnosed at necropsy and for which microscopic examination was not appropriate (e.g., missing anatomic parts) were not collected. Selected gross lesions for which a microscopic diagnosis would not be additive (e.g., deformity of tail) were saved but were not processed for microscopic evaluation.

All tissues were fixed in 10% neutral buffered formalin except testes, epididymides, and eyes which were fixed in Bouin's solution. The lungs were inflated with 10% neutral buffered formalin after weighing.

All tissues were processed, embedded in paraffin, cut at a nominal thickness of 5 micrometers, stained with hematoxylin and eosin (H&E) and examined microscopically.

J. Statistical Analyses

Descriptive statistics including mean, standard deviation, and standard error of the mean were used to summarize experimental data.

Significance was judged at $p < 0.05$.

Parameter	Preliminary Test	Method of Statistical Analysis	
		If preliminary test is not significant	If preliminary test is significant
Exposure Concentration Data	None	Descriptive statistics (e.g., mean, standard deviation)	
Particle Size Data	None	Regression analysis or probit analysis ⁽¹⁾	
Body Weight Body Weight Gain Organ Weight	Test for lack of trend ⁽²⁾	Sequential application ⁽³⁾ of the Jonckheere-Terpstra trend test ⁽⁴⁾	Preliminary tests for pairwise comparison
	OR ^a		
	Levene's test for homogeneity ⁽⁵⁾ and Shapiro-Wilk test ⁽⁶⁾ for normality ^b	One-way analysis of variance ⁽⁷⁾ followed with Dunnett's test ⁽⁸⁾	Kruskall-Wallis test ⁽⁹⁾ followed with Dunn's test ⁽¹⁰⁾
Clinical Pathology ^c	Levene's test for homogeneity ⁽⁵⁾ and Shapiro-Wilk test ⁽⁶⁾ for normality ^b	One-way analysis of variance ⁽⁷⁾ followed with Dunnett's test ⁽⁸⁾	Kruskall-Wallis test ⁽⁹⁾ followed with Dunn's test ⁽¹⁰⁾
Incidence of Clinical Observations	None	Cochran-Armitage test for trend ^{(7)d}	

- a Pairwise comparisons and associated preliminary tests were only conducted if the test for lack of trend was significant.
- b If the Shapiro-Wilk test was not significant but Levene's test was significant, a robust version of Dunnett's test was used.
- c When an individual observation was recorded as being less than a certain value, calculations were performed on half the recorded value. For example, if bilirubin was reported as <0.1, 0.05 was used for any calculations performed with that bilirubin data.
- d If the incidence was not significant, but a significant lack of fit occurred, then Fisher's Exact test⁽¹¹⁾ with a Bonferroni correction was used.

RESULTS AND DISCUSSION

In-Life Animal Measurements

A. Chamber Atmosphere Analysis of H-24267 (Tables 1-3, Appendices A-B)

Mean aerosol concentrations, particle size measurements, and chamber environmental conditions results are in tables 1, 2, and 3, respectively. Mean analytically determined aerosol concentrations of H-24267 for the 3 test chambers were 23, 110 and 600 mg/m³ (2 significant figures) for design concentrations of 25, 125, and 600 mg/m³, respectively. Based on 2 measurements per test concentration, the mass median aerodynamic equivalent diameter of the H-24267 aerosol ranged from 2.6 to 4.2 μ m. The chamber oxygen concentration measurements were 21%. The relative humidity for the chambers was between 35 and 84% and the chamber temperatures were between 21 and 26°C. The temperature and humidity in the chambers were close to that targeted with the exception of the %RH in the 600 mg/m³ chamber, and this was appreciably higher than targeted due to the presence of a high percentage of water (60 to 85%) in the test sample. Although the chamber humidity was high, these conditions are frequently encountered in inhalation studies with water-based aerosols and this was not expected to affect the study outcome.

B. Body Weights and Clinical Observations (Tables 4-6, Figure 2, Appendices C-D)

During the exposure period, there was a dose-related body weight depression that occurred especially in the 125 and 600 mg/m³ groups and all 3 groups gained less weight than controls. The H-24267 exposed rats appeared to resume a normal weight gain rate during the recovery period.

After the third exposure, slight lung noise occurred in 2 rats in the 600 mg/m³ group. These effects were not observed in the other test groups.

Sporadic incidences of alopecia were observed in some rats during the study. These findings were not dose-related and are frequently seen in inhalation studies where the animals are exposed in body restrainers.

Clinical Pathology Evaluations

A. Hematology/Coagulation (Tables 7-8, Appendix E)

There were no toxicologically significant changes in male rats for hematologic or coagulation parameters. All statistically significant changes were considered not toxicologically significant (non-adverse) or not related to compound administration. These changes are detailed below.

- The statistically significant minimal decreases in reticulocytes at day 11 in rats exposed to 125 or 600 mg/m³ were not correlated with any other supportive changes in erythrocyte parameters. Therefore, these changes were considered toxicologically insignificant and not compound related. Reticulocyte counts in H-24267-exposed rats at recovery were similar to control group values.

Statistically significant changes in the following parameters were minimal, did not occur in a concentration-dependent manner, and therefore were toxicologically insignificant:

- Decreased absolute neutrophils in rats exposed to 25 or 125 mg/m³ at day 11
- Decreased platelets in rats exposed to 25 mg/m³ at day 11
- Increased relative lymphocytes in rats exposed to 25 (day 11 only) or 125 (days 11 and 25) mg/m³
- Decreased relative neutrophils in rats exposed to 25 (day 11 only) or 125 (days 11 and 25) mg/m³.

B. Serum Chemistry (Table 9, Appendix E)

There were no toxicologically significant changes in male rats for clinical chemistry parameters. All statistically significant changes were considered not toxicologically significant (non-adverse) or not related to compound. These changes are detailed below.

- Statistically significant minimally decreased sodium, with minimally increased urea nitrogen and creatinine, occurred in rats exposed to 600 mg/m³ at day 11. These changes were mostly due to 1 animal (637830) who had moderate alterations in these 3 parameters. This rat also had dilute urine and nephropathy on histologic examination (grade mild), a background lesion that is commonly seen in CD-CRL IGS rats. The histologic lesion in this rat was not considered treatment related; therefore, the clinical pathology changes were also not considered related to treatment.
- Two other rats in the 600 mg/mg³ group had minimally increased urea nitrogen and creatinine (637835 and 637837) at day 11. These rats also had mildly increased albumin (with resulting

increased total protein and calcium,^d and decreased chloride at this same time-point. The renal concentrating ability of these rats was intact, and they had no histologic evidence of nephropathy. Therefore, although the changes discussed above were possibly related to treatment, they were not considered toxicologically significant in this group because there were no treatment related alterations in renal function (as measured by concentrating ability) or renal histology at either time-point.

- Minimally increased albumin in rats exposed to 25 or 125 mg/m³ (or 600 mg/m³, see burger dot 2 above) at day 11 was possibly related to treatment, but was not considered toxicologically significant because the changes were very slight (approximately 0.2 g/dl greater than the control group mean). At recovery (day 25), albumin concentrations in H-24267-exposed rats were similar to control group values, and within the reference range for the parameter (reference range: 4.3-4.9 g/dl).
- Minimally increased cholesterol in rats exposed to 125 or 600 mg/m³ at day 11, although possibly related to treatment, was not considered toxicologically significant because the change was slight and individual values generally were within the reference range for this parameter (reference range: 46-102 mg/dl). At recovery (day 25), cholesterol concentrations in H-24267-exposed rats were similar to control group values.

Statistically significant changes in the following parameters were minimal and did not occur in a concentration-dependant manner, or only occurred during the recovery phase, and therefore were toxicologically insignificant:

- Increased urea nitrogen and creatinine in rats exposed to 25 mg/m³ at day 11
- Decreased triglycerides in rats exposed to 25 mg/m³ at day 11
- Decreased globulins in rats exposed to 125 mg/m³ at day 25
- Increased chloride in rats exposed to 25 mg/m³ at day 11.

C. Urinalysis (Table 10, Appendix E)

There were no toxicologically significant changes in male rats for urinalysis parameters. All statistically significant changes were considered not toxicologically significant (non-adverse) or not related to compound. These changes are detailed below.

- Urine pH was moderately decreased (statistically significant) in rats exposed to 125 or 600 mg/m³ at day 11. Although decreased urine pH was possibly related to treatment, there were no correlative changes in other parameters (chloride, sodium, potassium) to suggest

d Calcium exists in serum in 2 forms, either bound to albumin or unbound ("ionized" calcium). Ionized calcium is the physiologically active form, and is tightly regulated. Increased albumin is necessarily associated with physiologically appropriate increased bound calcium, with resultant increased total calcium. However, ionized calcium is unaffected; therefore this change is not toxicologically significant.

alterations in systemic acid/base homeostasis. Therefore, this change was considered toxicologically insignificant. Urine pH was similar in all groups at the end of recovery (day 25).

- Total urinary fluoride was minimally increased in rats exposed to 125 mg/m³ at day 11. This statistically significant change did not occur in a concentration-dependant manner, and therefore was toxicologically insignificant:

D. Conclusions

There were no toxicologically significant changes in hematology, clinical chemistry, or urinalysis parameters. Therefore, under the conditions of this study and for the clinical pathology parameters measured, the no-observed-effect level (NOEL) was greater than 600 mg/m³, the highest exposure tested.

Anatomic Pathology Evaluations

A. Organ Weights

(Tables 11-12, Appendix F)

There were no compound-related changes in organ weights. At the end of the exposure period, statistically significant increases in all organ weights relative to body weight were present in the 125 and/or 600 mg/m³ groups. These changes were secondary to decreases in final body weights and thus were not indicative of direct target organ toxicity. All other statistically significant organ weight changes in the exposure groups were neither concentration-related nor associated with correlative microscopic changes and were thus considered spurious findings.

In the recovery groups, a statistically significant increase in lung weight relative to body weight was present in the 600 mg/m³ group. This change was not associated with changes in other lung weight parameters in this group or with correlative microscopic changes. The minimal findings in some rats in this group would not be expected to produce lung weight changes. Therefore, this finding was not considered to be compound-related.

B. Gross Observations

(Tables 13-14, Appendix G)

There were no compound-related gross findings. Only a few gross lesions were noted in the study. These occurred as single instances in treated and control groups and were lesions common to rats of this strain and age.

C. Microscopic Findings (Tables 15-16, Appendix G)

Compound-related microscopic changes consistent with slight irritation were present in the respiratory tract of rats in all treated groups. In the lungs, minimal inflammation confined to the centriacinar regions was present in all treated groups. Inflammation was characterized by mild thickening of alveolar duct bifurcations and adjacent alveolar septa due to mononuclear inflammatory cell infiltration. Slight hypertrophy of terminal bronchiolar epithelium was also present in association with the centriacinar inflammatory response. Lesions in the lungs were minimal at all exposure concentrations; however, changes were slightly more apparent with increasing concentration. In the larynx, minimal squamous metaplasia was present in all treated groups. Metaplasia occurred most consistently in the ventral laryngeal mucosa at the base of the epiglottis. Necrosis of cartilage overlying the laryngeal saccule was present in 1 rat in the 600 mg/m³ group. In the nose, hypertrophy of goblet cells was present in all treated groups and was most apparent in the mucosa of the pharyngeal duct.

Following an approximately 2-week recovery period, respiratory tract lesions were essentially reversible. Single occurrences of focal, very slight thickening of alveolar duct septa occurred in the 125 and 600 mg/m³ recovery groups. In addition, focal residual cartilage necrosis in the larynx occurred in 2/5 rats in the 600 mg/m³ recovery group.

All other microscopic changes observed occurred in low incidences across treated and control groups and/or are spontaneous lesions common to rats of this strain and age.

D. Conclusions

Under the conditions of this study, a no-observed-adverse effect level for pathology was not determined based on the presence of irritant lesions in the respiratory tract at all exposure concentrations tested. These changes were minimal and mostly reversible following a 2-week recovery period.

CONCLUSIONS

During the exposure period there was a dose-related body weight depression occurred primarily in the 125 and 600 mg/m³ groups and all 3 test groups gained less weight than the controls. The H-24267 exposed rats resumed a normal weight gain rate during the recovery period.

Clinical pathology evaluations at both evaluation times showed no toxicologically significant changes in hematology, clinical chemistry, or urinalysis parameters, including urinary fluoride.

Weight analysis of major organs showed no effects attributable to the test compound. Histological findings were confined to the respiratory tract; no significant findings were observed in any other evaluated organs. Minimal, dose-related histologic effects attributable to the test compound were found in the respiratory tract of all treated groups at the end of the 2-week exposure period. The effects were consistent with minimal irritation and were slightly more apparent with increasing dose. These effects occurred throughout the respiratory tract, including the nose, larynx, and lung. In the lungs, inflammation was characterized by mild thickening of alveolar duct bifurcations and adjacent alveolar septa due to mononuclear inflammatory cell infiltration. Slight hypertrophy of terminal bronchiolar epithelium was also present in association with the centriacinar inflammatory response. In the larynx, minimal squamous metaplasia was present in all treated groups. Necrosis of cartilage overlying the laryngeal saccule was present in 1 rat in the 600 mg/m group. In the nose, hypertrophy of goblet cells was present in all treated groups and was most apparent in the mucosa of the pharyngeal duct.

Following an approximately 2-week recovery period, respiratory tract lesions were essentially reversible. Single occurrences of focal, very slight thickening of alveolar duct septa occurred in the 125 and 600 mg/m³ recovery groups. In addition, focal residual cartilage necrosis in the larynx occurred in 2/5 rats in the 600 mg/m³ recovery group.

Based on the finding of minimal respiratory tract inflammation observed in all exposed groups including the lowest concentration tested, 25 mg/m³, a no-observed-adverse-effect-level (NOAEL) was not determined for repeated aerosol exposures to H-24267 in rats.

RECORDS AND SAMPLE STORAGE

Specimens (if applicable), raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware (formerly known as the E. I. du Pont de Nemours and Company Records Management Center). Clinical pathology slides and raw data will be retained at Haskell Laboratory, Newark, Delaware. Wet specimens and records related to clinical pathology analyses were retained by DuPont Pharmaceuticals Company.

REFERENCES

1. Calculation described in Sierra Instruments, Inc., Bulletin 7-79-219IM, Instruction Manual: Series 210 Ambient Cascade Impactors and Cyclone Preseparators.
2. Draper, N.R. and Smith, H. (1981). Applied Regression Analysis, 2nd edition, pp 266-273. Wiley, New York.
3. Selwyn, M.R. (1995). The use of trend tests to determine a no-observable-effect level in animal safety studies. *Journal of the American College of Toxicology* 14(2), 158-168.
4. Jonckheere, A.R. (1954). A distribution-free K-sample test against ordered alternatives. *Biometrika* 41, 133-145.
5. Levene, H. (1960). Robust test for equality of variances. *Contributions to Probability and Statistics* (J. Olkin, ed.), pp 278-292. Stanford University Press, Palo Alto.
6. Shapiro, S.S. and Wilk, M.B. (1965). An analysis of variance test for normality (complete samples). *Biometrika* 52, 591-611.
7. Snedecor, G.W. and Cochran, W.G. (1967). *Statistical Methods*, 6th edition, pp 246-248 and 349-352. The Iowa State University Press, Iowa.
8. Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. *J. Amer. Statist. Assoc.* 50, 1096-1121.
9. Kruskal, W.H. and Wallis, W.A. (1952). Use of ranks in one-criterion analysis of variance. *J. Amer. Statist. Assoc.* 47, 583-621.
10. Dunn, O.J. (1964). Multiple contrasts using rank sums. *Technometrics* 6, 241-252.
11. Fisher, R.A. (1985). *Statistical Methods for Research Workers*, 13th edition. Haffner, New York.

TABLES

TABLES

EXPLANATORY NOTES

ABBREVIATIONS:**Tables 1 and 3**

- S.D. - standard deviation
S.E.M. - standard error of the mean
mg/m³ - milligrams per cubic meter
n - number of samples

Table 7

- RBC - red blood cell count
HGB - hemoglobin
HCT - hematocrit
MCV - mean corpuscular volume
MCH - mean corpuscular hemoglobin
MCHC - mean corpuscular hemoglobin concentration
RDW - red cell distribution width
ARET - absolute reticulocyte count
NRBC - nucleated red blood cell count
WBC - white blood cell count
ANEU - absolute neutrophil (all forms)
ANPR - absolute neutrophil precursor
ALYM - absolute lymphocyte
AMON - absolute monocyte
AEOS - absolute eosinophil
ABAS - absolute basophil
ALUC - absolute large unstained cell
ABLT - absolute blast leukocyte
AMSC - absolute miscellaneous leukocyte
PLT - platelet count
BASO - percent basophil
BLST - percent blast leukocyte
EOS - percent eosinophil
LUC - percent large unstained cell
LYMP - percent lymphocyte
MISC - percent miscellaneous leukocyte
MONO - percent monocyte
NEUT - percent neutrophil
NPRE - percent neutrophil precursor

TABLES

EXPLANATORY NOTES (Continued)

ABBREVIATIONS: (Continued)

Table 8

PT	-	prothrombin time
APTT	-	activated partial thromboplastin time

Table 9

AST	-	aspartate aminotransferase
ALT	-	alanine aminotransferase
SDH	-	sorbitol dehydrogenase
ALKP	-	alkaline phosphatase
BILI	-	total bilirubin
BUN	-	urea nitrogen
CREA	-	creatinine
CHOL	-	cholesterol
TRIG	-	triglycerides
GLUC	-	glucose
TP	-	total protein
ALB	-	albumin
GLOB	-	globulin
CALC	-	calcium
IPHS	-	inorganic phosphorous
NA	-	sodium
K	-	potassium
CL	-	chloride
PFLU	-	plasma fluoride

Table 10

VOL	-	volume
UOSM	-	urine osmolality
SG	-	specific gravity
pH	-	the logarithm of the reciprocal of the hydrogen ion concentration
URO	-	urobilinogen
UFLU	-	urine fluoride

TABLES

EXPLANATORY NOTES (Continued)**NOTES:****Tables 1 - 3**

Values are reported to 2 significant figures. Means and standard errors of the mean were calculated prior to rounding values to 2 significant figures.

Tables 7 - 10

When an individual observation is recorded as being less than a certain value, calculations are performed on half the recorded value. For example, if bilirubin is reported as <0.1, 0.05 is used for any calculations performed with that bilirubin data.

TABLE 1

CHAMBER CONCENTRATIONS OF H-24267

DESIGN CONCENTRATION (mg/m ³)	MEASURED CONCENTRATION ^a (mg/m ³)			
	MEAN	S.E.M.	RANGE	n
0	0	0	0	54
25	23	2.0	4.0 - 70	54
125	110	4.6	18 - 200	54
600	600	25	85 - 960	54

a Values represent the mean, standard error of the mean (S.E.M.), and range for all samples obtained from n exposures.

TABLE 2

PARTICLE SIZE DISTRIBUTION OF H-24267

DESIGN CONCENTRATION (mg/m ³)	TEST DAY	MASS MEDIAN AERODYNAMIC DIAMETER (μm)	GEOMETRIC STANDARD DEVIATION	% PARTICLES BY MASS		
				<1 μm	<3 μm	<10 μm
25	4	3.2	2.5	13	48	86
	11	2.6	2.2	12	58	96
125	3	4.0	3.1	11	40	84
	10	2.6	2.2	14	62	96
600	2	3.9	3.0	11	42	82
	9	4.2	2.2	3.0	33	88

TABLE 3

CHAMBER ENVIRONMENTAL CONDITIONS

DESIGN CONCENTRATION (mg/m ³) ^a	TEMPERATURE (°C)	RELATIVE HUMIDITY (%)	AIRFLOW (L/min)	n
0	22 - 26	35 - 50	30	9
25	22 - 26	38 - 54	30	9
125	22 - 25	37 - 61	30	9
600	21 - 24	65 - 84	30	9

a Values represent the range for all samples obtained from n exposures.

TABLE 4
MEAN BODY WEIGHTS OF MALE RATS

DAYS ON TEST	MEAN BODY WEIGHTS (g)			
	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
<i>EXPOSURE</i>				
DAY 0	291.8 23.4(10)	288.9 16.3(10)	295.5 10.2(10)	298.5 17.4(10)
DAY 1	294.4 23.3(10)	284.6 16.3(10)	288.0 9.7(10)	286.1 18.1(10)
DAY 2	301.6 25.0(10)	287.2 15.2(10)	291.1 10.7(10)	287.1 19.3(10)
DAY 3	306.9 24.7(10)	289.3 15.4(10)	296.7 9.2(10)	285.9# 21.0(10)
DAY 4	309.8 25.1(10)	293.7 16.7(10)	299.2 10.6(10)	287.4# 22.1(10)
DAY 7	328.4 28.6(10)	315.8 18.0(10)	322.9 11.6(10)	313.2 22.5(10)
DAY 8	332.6 28.0(10)	316.7# 18.2(10)	319.1# 10.2(10)	309.1# 24.5(10)
DAY 9	332.6 29.7(10)	317.9 19.5(10)	315.8# 11.6(10)	309.7# 24.5(10)
DAY 10	338.7 29.0(10)	320.5 21.3(10)	318.7# 13.1(10)	309.0# 25.6(10)

TABLE 4 (Continued)

MEAN BODY WEIGHTS OF MALE RATS

DAYS ON TEST	MEAN BODY WEIGHTS (g)			
	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
<i>RECOVERY</i>				
DAY 11	306.4 25.7(10)	286.8# 17.7(10)	287.1# 14.7(10)	272.2# 22.6(10)
DAY 14	338.6 38.9(5)	313.8 25.9(5)	337.2 16.4(5)	310.6 37.3(5)
DAY 18	367.3 44.0(5)	340.9 29.3(5)	366.9 21.1(5)	343.0 44.2(5)
DAY 22	391.7 45.0(5)	360.6 32.5(5)	391.8 23.8(5)	363.5 47.2(5)
DAY 25	375.8 47.2(5)	348.9 35.8(5)	379.3 22.2(5)	354.0 47.2(5)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

Statistically significant difference from control at $p < 0.05$ by trend test (Jonckheere-Terpstra).

TABLE 5
MEAN BODY WEIGHT GAINS OF MALE RATS

DAYS ON TEST	MEAN BODY WEIGHT GAINS (g)			
	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
<i>EXPOSURE</i>				
DAY 0 - DAY 1	2.6 6.1(10)	-4.3# 3.8(10)	-7.6# 3.9(10)	-12.4# 6.1(10)
DAY 1 - DAY 2	7.2 2.8(10)	2.6# 2.5(10)	3.1# 2.8(10)	1.0# 4.9(10)
DAY 2 - DAY 3	5.3 2.7(10)	2.1 2.5(10)	5.7 4.5(10)	-1.1# 3.5(10)
DAY 3 - DAY 4	2.9 3.7(10)	4.4 1.8(10)	2.4 2.9(10)	1.4 6.5(10)
DAY 4 - DAY 7	18.6 5.3(10)	22.1 5.1(10)	23.7# 4.3(10)	25.9# 6.1(10)
DAY 7 - DAY 8	4.2 3.2(10)	0.9# 2.0(10)	-3.8# 5.0(10)	-4.1# 3.6(10)
DAY 8 - DAY 9	-0.1 10.5(10)	1.2 2.9(10)	-3.2# 3.7(10)	0.6# 4.0(10)
DAY 9 - DAY 10	6.1 7.5(10)	2.6 2.8(10)	2.9 3.3(10)	-0.7 6.1(10)
DAY 10 - DAY 11 ^a	-32.3 8.6(10)	-33.7 7.5(10)	-31.6 5.0(10)	-36.8 5.8(10)

TABLE 5 (Continued)

MEAN BODY WEIGHT GAINS OF MALE RATS

DAYS ON TEST	MEAN BODY WEIGHT GAINS (g)			
	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
<i>RECOVERY</i>				
DAY 11 - DAY 14	37.6 11.3(5)	34.6 5.7(5)	43.2 8.6(5)	42.6 7.7(5)
DAY 14 - DAY 18	28.7 7.6(5)	27.1 5.1(5)	29.7 6.8(5)	32.4 7.4(5)
DAY 18 - DAY 22	24.4 3.3(5)	19.7 5.6(5)	24.9 5.2(5)	20.5 5.5(5)
DAY 22 - DAY 25 ^a	-15.9 2.9(5)	-11.7 4.9(5)	-12.4# 1.9(5)	-9.5# 2.1(5)
<i>OVERALL</i>				
DAY 0 - DAY 10	46.9 14.7(10)	31.6# 13.1(10)	23.2# 9.1(10)	10.5# 10.8(10)
DAY 11 - DAY 25	74.5 17.1(5)	69.7 16.2(5)	85.3 11.6(5)	86.0 16.6(5)
DAY 0 - DAY 25	89.8 23.6(5)	67.9 30.3(5)	84.1 13.0(5)	59.6 23.7(5)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

Statistically significant difference from control at $p < 0.05$ by trend test (Jonckheere-Terpstra).

a Weight losses due to fasting of rats prior to clinical pathology evaluations.

TABLE 6

SUMMARY OF CLINICAL OBSERVATIONS IN MALE RATS AT WEIGHING

	GROUP:	I	III	V	VII
DESIGN CONCENTRATION (mg/m ³):		0	25	125	600
ANIMAL COUNT:		10	10	10	10
Hair Loss					
Face, Right					
Incidence		0 (0%)	1 (10%)	0 (0%)	0 (0%)
Observed		0	3	0	0
Mean onset (Days)		-	8	-	-
Forepaw, Left					
Incidence		0 (0%)	0 (0%)	1 (10%)	0 (0%)
Observed		0	0	1	0
Mean onset (Days)		-	-	7	-
Forepaw, Bilateral					
Incidence		0 (0%)	0 (0%)	2 (20%)	0 (0%)
Observed		0	0	10	0
Mean onset (Days)		-	-	5	-
Forelimb, Bilateral					
Incidence		0 (0%)	0 (0%)	1 (10%)	0 (0%)
Observed		0	0	5	0
Mean onset (Days)		-	-	4	-
Hair Loss Totals					
Incidence		0 (0%)	1 (10%)	2 (20%)	0 (0%)
Observed		0	3	16	0
Mean onset (Days)		-	8	5	-
Wound, Superficial, Face					
Incidence		0 (0%)	1 (10%)	0 (0%)	0 (0%)
Observed		0	5	0	0
Mean onset (Days)		-	1	-	-

Incidence - The number of animals (percent of group) for which an observation was recorded.

Observed - The total number of test days the observation was recorded for animals in the group.

Mean onset (Days) - The mean of the test days each observation was first recorded for that group.

A dash indicates a clinical observation was not observed, therefore, there is no mean onset day.

There were no statistically significant differences from control at $p < 0.05$.

TABLE 7

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
RBC (x10 ⁶ /μL)				
DAY 11	7.57 0.32(10)	7.74 0.64(10)	7.60 0.35(10)	8.05 0.49(10)
DAY 25	8.12 0.42(5)	8.51 0.31(5)	7.67 0.30(5)	8.05 0.38(5)
HGB (g/dL)				
DAY 11	15.2 0.7(10)	15.2 0.9(10)	15.3 0.4(10)	15.9 0.7(10)
DAY 25	15.8 0.4(5)	15.9 0.6(5)	15.4 0.4(5)	15.5 0.2(5)
HCT (%)				
DAY 11	47.3 2.0(10)	47.4 3.2(10)	47.1 1.3(10)	49.2 2.0(10)
DAY 25	48.2 1.8(5)	49.5 1.7(5)	47.2 1.3(5)	47.7 0.6(5)
MCV (fl)				
DAY 11	62.4 1.6(10)	61.3 2.1(10)	62.0 1.8(10)	61.2 1.7(10)
DAY 25	59.4 1.2(5)	58.2 0.3(5)	61.6 1.8(5)	59.3 2.2(5)
MCH (pg)				
DAY 11	20.1 0.5(10)	19.7 0.7(10)	20.2 0.8(10)	19.8 0.5(10)
DAY 25	19.4 0.6(5)	18.7 0.3(5)	20.1 0.6(5)	19.3 0.8(5)
MCHC (g/dL)				
DAY 11	32.1 0.6(10)	32.1 0.5(10)	32.5 0.6(10)	32.3 0.5(10)
DAY 25	32.8 0.5(5)	32.1 0.5(5)	32.7 0.4(5)	32.5 0.4(5)
RDW (%)				
DAY 11	13.0 0.6(10)	13.1 0.6(10)	13.4 0.7(10)	13.5 0.5(10)
DAY 25	13.3 0.5(5)	13.3 0.2(5)	13.2 0.3(5)	13.6 0.4(5)

TABLE 7 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
ARET (x10 ³ /μL)				
DAY 11	234.9 30.6(10)	203.7 29.0(10)	174.1* 31.3(10)	159.6* 35.1(10)
DAY 25	261.4 28.6(5)	266.2 11.2(5)	258.2 31.6(5)	253.2 35.5(5)
NRBC (/100 WBC)				
DAY 11 ^a				
DAY 25 ^b				
WBC (x10 ³ /μL)				
DAY 11	13.11 2.63(10)	12.77 2.93(10)	12.32 1.56(10)	13.05 4.43(10)
DAY 25	14.68 5.23(5)	14.91 4.15(5)	14.38 3.25(5)	14.47 2.68(5)
ANEU (x10 ³ /μL)				
DAY 11	2.09 0.84(10)	1.38@ 0.49(10)	1.27@ 0.26(10)	1.66 0.75(10)
DAY 25	2.65 1.30(5)	2.47 0.67(5)	1.77 0.63(5)	2.00 0.29(5)
ANPR (x10 ³ /μL)				
DAY 11 ^a				
DAY 25 ^b				
ALYM (x10 ³ /μL)				
DAY 11	10.24 2.04(10)	10.65 2.59(10)	10.23 1.37(10)	10.53 3.66(10)
DAY 25	11.23 3.75(5)	11.48 3.37(5)	11.75 2.58(5)	11.59 2.39(5)
AMON (x10 ³ /μL)				
DAY 11	0.37 0.10(10)	0.29 0.16(10)	0.35 0.15(10)	0.35 0.25(10)
DAY 25	0.35 0.16(5)	0.43 0.08(5)	0.37 0.10(5)	0.38 0.03(5)

TABLE 7 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
AEOS (x10 ³ /μL)				
DAY 11	0.12 0.04(10)	0.11 0.04(10)	0.20 0.23(10)	0.15 0.08(10)
DAY 25	0.14 0.04(5)	0.15 0.07(5)	0.10 0.03(5)	0.10 0.04(5)
ABAS (x10 ³ /μL)				
DAY 11	0.08 0.03(10)	0.09 0.06(10)	0.04 0.03(10)	0.07 0.05(10)
DAY 25	0.09 0.04(5)	0.09 0.06(5)	0.09 0.03(5)	0.09 0.02(5)
ALUC (x10 ³ /μL)				
DAY 11	0.22 0.06(10)	0.24 0.13(10)	0.17 0.10(10)	0.24 0.21(10)
DAY 25	0.23 0.07(5)	0.29 0.18(5)	0.29 0.06(5)	0.31 0.13(5)
ABLT (x10 ³ /μL)				
DAY 11 ^a				
DAY 25 ^b				
AMSC (x10 ³ /μL)				
DAY 11 ^a				
DAY 25 ^b				
PLT (x10 ³ /μL)				
DAY 11	1082 145(7)	919* 148(9)	946 120(9)	926 95(9)
DAY 25	1088 99(4)	946 109(3)	1004 113(5)	943 88(5)
BASO (%)				
DAY 11	0.6 0.2(10)	0.7 0.5(10)	0.4 0.3(10)	0.5 0.3(10)
DAY 25	0.6 0.3(5)	0.6 0.2(5)	0.6 0.2(5)	0.6 0.1(5)

TABLE 7 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
BLST (%)				
DAY 11 ^a				
DAY 25 ^b				
EOS (%)				
DAY 11	0.9	0.9	1.6	1.2
	0.3(10)	0.3(10)	1.9(10)	0.7(10)
DAY 25	1.0	1.0	0.7	0.7
	0.3(5)	0.5(5)	0.1(5)	0.3(5)
LUC (%)				
DAY 11	1.7	1.9	1.4	1.8
	0.5(10)	1.0(10)	0.8(10)	1.2(10)
DAY 25	1.6	1.8	2.0	2.1
	0.4(5)	0.6(5)	0.3(5)	0.7(5)
LYMP (%)				
DAY 11	78.2	83.2*	83.0*	80.5
	5.0(10)	3.6(10)	3.2(10)	4.1(10)
DAY 25	76.9	76.7	81.9*	79.9
	3.0(5)	3.1(5)	1.4(5)	2.1(5)
MISC (%)				
DAY 11 ^a				
DAY 25 ^b				
MONO (%)				
DAY 11	2.9	2.2	2.9	2.6
	0.7(10)	0.9(10)	1.3(10)	1.6(10)
DAY 25	2.4	2.9	2.7	2.7
	0.6(5)	0.5(5)	0.9(5)	0.4(5)
NEUT (%)				
DAY 11	15.7	11.0*	10.3*	13.0
	4.5(10)	3.7(10)	1.6(10)	3.6(10)
DAY 25	17.6	16.9	12.1*	14.1
	2.9(5)	3.1(5)	2.2(5)	2.2(5)

TABLE 7 (Continued)

SUMMARY OF HEMATOLOGY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
NPRES (%)				
DAY 11 ^a				
DAY 25 ^b				

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

- a When this analysis was performed, valid measurements were taken on only a few animals from the group. Data from this small sample size did not add value to this summary table. Individual data are reported in the Clinical Pathology appendix.
- b Measurements for all animals were not taken or not performed. Data of this type did not add value to this summary table. Individual data are reported in the Clinical Pathology appendix.

* Statistically significant difference from control at $p < 0.05$ by parametric test (Dunnett/Tamhane-Dunnett).

@ Statistically significant difference from control at $p < 0.05$ by nonparametric test (Dunn's).

TABLE 8

SUMMARY OF COAGULATION VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
PT (seconds)				
DAY 11	15.8 1.5(5)	15.2 0.3(5)	15.5 1.0(4)	15.1 0.4(5)
DAY 25	14.8 0.6(5)	15.4 0.8(5)	14.5 0.3(5)	14.7 0.9(5)
APTT (seconds)				
DAY 11	19.9 6.1(5)	21.0 3.6(5)	17.2 1.8(4)	20.1 3.6(5)
DAY 25	19.0 2.8(5)	19.1 4.0(5)	16.7 1.4(5)	17.1 2.4(5)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

There were no statistically significant differences from control at $p < 0.05$.

TABLE 9

SUMMARY OF SERUM CHEMISTRY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
AST (U/L)				
DAY 11	95 16(10)	98 19(10)	83 12(10)	89 15(10)
DAY 25	95 13(5)	104 13(5)	92 16(5)	97 19(5)
ALT (U/L)				
DAY 11	38 6(10)	43 5(10)	35 5(10)	45 11(10)
DAY 25	45 4(5)	44 4(5)	40 3(5)	43 6(5)
SDH (U/L)				
DAY 11	17.6 3.1(10)	16.3 2.7(10)	15.5 2.8(10)	16.2 3.6(10)
DAY 25	21.5 2.3(5)	22.5 4.1(5)	20.2 3.0(5)	19.7 6.1(5)
ALKP (U/L)				
DAY 11	219 38(10)	193 27(10)	199 51(10)	181 33(10)
DAY 25	200 39(5)	185 17(5)	192 38(5)	169 36(5)
BILI (mg/dL)				
DAY 11	0.08 0.03(10)	0.08 0.04(10)	0.07 0.03(10)	0.10 0.05(10)
DAY 25	0.11 0.04(5)	0.13 0.05(5)	0.10 0.03(5)	0.13 0.02(5)
BUN (mg/dL)				
DAY 11	13 2(10)	17@ 2(10)	15 2(10)	21@ 6(10)
DAY 25	14 2(5)	16 1(5)	14 1(5)	16 2(5)
CREA (mg/dL)				
DAY 11	0.33 0.05(10)	0.40@ 0.05(10)	0.38 0.05(10)	0.45@ 0.10(10)
DAY 25	0.42 0.05(5)	0.48 0.06(5)	0.42 0.03(5)	0.37 0.05(5)

TABLE 9 (Continued)

SUMMARY OF SERUM CHEMISTRY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
CHOL (mg/dL)				
DAY 11	65 20(10)	65 12(10)	83* 18(10)	85* 15(10)
DAY 25	68 12(5)	75 16(5)	76 18(5)	76 13(5)
TRIG (mg/dL)				
DAY 11	45 14(10)	32* 12(10)	40 10(10)	38 9(10)
DAY 25	60 28(5)	61 16(5)	72 24(5)	43 7(5)
GLUC (mg/dL)				
DAY 11	90 7(10)	85 6(10)	89 10(10)	89 5(10)
DAY 25	95 11(5)	89 10(5)	95 11(5)	92 9(5)
TP (g/dL)				
DAY 11	6.1 0.2(10)	6.3 0.3(10)	6.2 0.2(10)	6.5* 0.3(10)
DAY 25	6.9 0.4(5)	7.0 0.2(5)	6.6 0.2(5)	6.8 0.2(5)
ALB (g/dL)				
DAY 11	4.2 0.1(10)	4.4* 0.2(10)	4.4* 0.1(10)	4.5* 0.2(10)
DAY 25	4.6 0.2(5)	4.8 0.1(5)	4.7 0.2(5)	4.7 0.2(5)
GLOB (g/dL)				
DAY 11	1.9 0.2(10)	1.9 0.2(10)	1.8 0.1(10)	2.0 0.2(10)
DAY 25	2.2 0.3(5)	2.2 0.1(5)	1.9* 0.0(5)	2.1 0.2(5)
CALC (mg/dL)				
DAY 11	10.9 0.4(10)	10.9 0.3(10)	11.0 0.2(10)	11.3@ 0.3(10)
DAY 25	10.9 0.2(5)	10.9 0.2(5)	10.8 0.3(5)	10.9 0.3(5)

TABLE 9 (Continued)

SUMMARY OF SERUM CHEMISTRY VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
IPHS (mg/dL)				
DAY 11	10.0 1.0(10)	9.7 0.4(10)	9.7 0.4(10)	9.6 0.7(10)
DAY 25	8.8 0.7(5)	8.7 0.7(5)	8.6 0.5(5)	9.2 0.6(5)
NA (mmol/L)				
DAY 11	149.1 1.4(10)	149.0 1.4(10)	148.6 1.0(10)	147.2* 2.2(10)
DAY 25	150.5 1.1(5)	150.5 0.9(5)	150.9 1.4(5)	150.1 1.4(5)
K (mmol/L)				
DAY 11	6.21 0.33(10)	6.18 0.30(10)	6.04 0.24(10)	5.93 0.31(10)
DAY 25	5.98 0.41(5)	6.27 0.07(5)	5.96 0.36(5)	6.00 0.20(5)
CL (mmol/L)				
DAY 11	95.4 1.0(10)	97.8* 1.3(10)	96.4 2.1(10)	93.4 2.4(10)
DAY 25	95.9 1.7(5)	97.0 2.0(5)	96.8 1.0(5)	97.0 1.2(5)
PFLU (μg/mL)				
DAY 11	0.1 0.0(5)	0.1 0.0(5)	0.1 0.0(5)	0.1 0.0(5)
DAY 25	0.1 0.0(5)	0.1 0.0(5)	0.1 0.0(5)	0.1 0.0(5)

Data arranged as: Mean

Standard deviation (Number of values included in calculation)

* Statistically significant difference from control at $p < 0.05$ by parametric test (Dunnett/Tamhane-Dunnett).@ Statistically significant difference from control at $p < 0.05$ by nonparametric test (Dunn's).

TABLE 10

SUMMARY OF URINALYSIS VALUES FOR MALE RATS

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
VOL (mL)				
DAY 11	9.6 6.7(9)	9.0 3.5(10)	9.3 5.4(10)	10.6 3.7(10)
DAY 25	12.5 7.6(5)	12.7 5.7(5)	13.8 4.4(5)	10.6 8.3(5)
UOSM (mOsm)				
DAY 11	914 342(9)	830 223(10)	854 461(10)	732 270(10)
DAY 25	868 444(5)	705 248(5)	661 209(5)	957 425(5)
SG				
DAY 11	1.029 0.011(9)	1.026 0.006(10)	1.029 0.015(10)	1.024 0.008(10)
DAY 25	1.028 0.014(5)	1.022 0.007(5)	1.021 0.005(5)	1.030 0.013(5)
pH				
DAY 11	6.4 0.6(9)	6.2 0.4(10)	5.5* 0.5(10)	5.4* 0.3(10)
DAY 25	6.5 0.4(5)	6.3 0.3(5)	6.1 0.5(5)	6.0 0.4(5)
URO (EU/dL)				
DAY 11	0.3 0.3(9)	0.2 0.0(10)	0.2 0.0(10)	0.2 0.0(10)
DAY 25	0.2 0.0(5)	0.2 0.0(5)	0.2 0.0(5)	0.2 0.0(5)
UFLU (μg)				
DAY 11	9.4 3.3(9)	10.8 3.1(10)	14.8* 4.9(10)	12.9 2.8(10)
DAY 25	11.5 4.1(5)	12.1 2.6(5)	15.3 2.7(5)	12.5 4.4(5)

Data arranged as: Mean

Standard deviation (Number of values included in calculation)

* Statistically significant difference from control at $p < 0.05$ by parametric test (Dunnett/Tamhane-Dunnett).

TABLE 11

MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS
DAY 11 SACRIFICE

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
MEAN FINAL BODY AND ABSOLUTE ORGAN WEIGHTS (grams)				
LIVER	10.54880 0.55032(5)	9.50840 0.56907(5)	9.85100 1.02333(5)	10.03180 0.67382(5)
KIDNEYS	2.83220 0.31214(5)	2.76240 0.25635(5)	2.66800 0.19941(5)	2.76800 0.10556(5)
LUNGS	1.80220 0.12323(5)	1.49680 0.08472(5)	2.01000 0.33803(5)	1.80380 0.20042(5)
BRAIN	1.93720 0.05766(5)	1.86640 0.08421(5)	1.92360 0.09308(5)	1.90600 0.07562(5)
TESTES	2.84160 0.38756(5)	3.33860* 0.19602(5)	3.28120 0.09154(5)	2.97040 0.30940(5)
FINAL BODY WEIGHT (grams)	311.80000 11.18928(5)	294.40000*# 6.22896(5)	280.20000*# 10.40192(5)	276.40000*# 10.31019(5)
MEAN RELATIVE ORGAN WEIGHTS (% of body weight)				
LIVER/ FINAL BODY*100	3.38205 0.08260(5)	3.22938 0.17369(5)	3.50953 0.24956(5)	3.62979# 0.20580(5)
KIDNEYS/ FINAL BODY*100	0.90831 0.09411(5)	0.93744 0.07309(5)	0.95157 0.04758(5)	1.00204# 0.03924(5)
LUNGS/ FINAL BODY*100	0.57810 0.03517(5)	0.50818 0.01956(5)	0.71656* 0.11089(5)	0.65263# 0.06705(5)

TABLE 11 (Continued)

MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS
DAY 11 SACRIFICE

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
MEAN RELATIVE ORGAN WEIGHTS (% of body weight)				
BRAIN/ FINAL BODY*100	0.62189 0.02732(5)	0.63389 0.02293(5)	0.68680*# 0.03039(5)	0.68962*# 0.01266(5)
TESTES/ FINAL BODY*100	0.91322 0.13523(5)	1.13395*# 0.05970(5)	1.17268*# 0.06463(5)	1.07356*# 0.08925(5)
MEAN RELATIVE ORGAN WEIGHTS (organ to brain weight ratio)				
LIVER/BRAIN	5.44863 0.31536(5)	5.09267 0.12069(5)	5.11662 0.40345(5)	5.26273 0.26177(5)
KIDNEYS/BRAIN	1.46104 0.14027(5)	1.47861 0.10078(5)	1.38671 0.07224(5)	1.45356 0.06636(5)
LUNGS/BRAIN	0.93029 0.05627(5)	0.80245* 0.04060(5)	1.04812 0.18989(5)	0.94588 0.08873(5)
TESTES/BRAIN	1.46377 0.16187(5)	1.79131* 0.12406(5)	1.70816* 0.07573(5)	1.55774 0.14152(5)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

There were no statistically significant differences from control at $p < 0.05$.

Statistically significant difference from control at $p < 0.05$ by trend test (Jonckheere-Terpstra).

* Statistically significant difference from control at $p < 0.05$ by parametric test (Dunnett/Tamhane-Dunnett).

TABLE 12

MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS
DAY 25 SACRIFICE

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
MEAN FINAL BODY AND ABSOLUTE ORGAN WEIGHTS (grams)				
LIVER	11.81520 1.54485(5)	10.82700 1.99882(5)	12.56100 0.95760(5)	11.87300 2.05716(5)
KIDNEYS	3.18140 0.42244(5)	2.87560 0.34528(5)	3.32220 0.24865(5)	3.18700 0.42985(5)
LUNGS	1.78640 0.25665(5)	1.69700 0.19552(4)	1.87220 0.14939(5)	1.91360 0.29441(5)
BRAIN	1.94560 0.16046(5)	2.00780 0.11708(5)	2.06580 0.10822(5)	1.99020 0.10492(5)
TESTES	3.17320 0.31452(5)	3.29320 0.34343(5)	2.82860 0.52816(5)	3.27060 0.28905(5)
FINAL BODY WEIGHT (grams)				
	375.80000 47.17112(5)	348.90000 35.83001(5)	379.32000 22.24718(5)	354.00000 47.17536(5)
MEAN RELATIVE ORGAN WEIGHTS (% of body weight)				
LIVER/ FINAL BODY*100	3.14308 0.11223(5)	3.08887 0.32592(5)	3.30980 0.11230(5)	3.34305 0.25029(5)
KIDNEYS/ FINAL BODY*100	0.84605 0.02050(5)	0.82327 0.02397(5)	0.87592 0.04028(5)	0.90275 0.07877(5)
LUNGS/ FINAL BODY*100	0.47483 0.01857(5)	0.48396 0.06297(4)	0.49457 0.04540(5)	0.53948# 0.02622(5)

TABLE 12 (Continued)

MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS
DAY 25 SACRIFICE

TEST/ PERIOD	Group I 0 mg/m ³	Group III 25 mg/m ³	Group V 125 mg/m ³	Group VII 600 mg/m ³
BRAIN/ FINAL BODY*100	0.52227 0.06124(5)	0.57859 0.04583(5)	0.54580 0.03818(5)	0.56807 0.05830(5)
TESTES/ FINAL BODY*100	0.85014 0.09459(5)	0.94481 0.04910(5)	0.74234 0.10856(5)	0.93325 0.11274(5)
MEAN RELATIVE ORGAN WEIGHTS (organ to brain weight ratio)				
LIVER/BRAIN	6.07890 0.66519(5)	5.36315 0.69015(5)	6.09520 0.56827(5)	5.94192 0.80947(5)
KIDNEYS/BRAIN	1.63796 0.19474(5)	1.42971 0.11537(5)	1.61037 0.12665(5)	1.59608 0.14198(5)
LUNGS/BRAIN	0.91981 0.12105(5)	0.83631 0.11746(4)	0.91065 0.11247(5)	0.95879 0.11860(5)
TESTES/BRAIN	1.64389 0.25262(5)	1.64009 0.14469(5)	1.37226 0.26123(5)	1.64189 0.08712(5)

Data arranged as: Mean
Standard deviation (Number of values included in calculation)

Statistically significant difference from control at $p < 0.05$ by trend test (Jonckheere-Terpstra).

TABLE 13
INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	LESION INCIDENCE (Numeric)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
LIVER		(5) 4	(5) 5	(5) 5	(5) 5
NO ABNORMALITY DETECTED					
DEFORMITY, IRREGULAR, MIDDLE.		1			
DISCOLORATION, YELLOW, LEFT.		1			
KIDNEYS		(5) 5	(5) 4 1	(5) 5	(5) 5
NO ABNORMALITY DETECTED					
DILATATION, UNILATERAL, PELVIS.					
LUNGS		(5) 5	(5) 5	(5) 5	(5) 5
NO ABNORMALITY DETECTED					
HEART		(5) 5	(5) 5	(5) 5	(5) 5
NO ABNORMALITY DETECTED					
SPLEEN		(5) 5	(5) 4 1	(5) 5	(5) 5
NO ABNORMALITY DETECTED					
DEFORMITY, IRREGULAR.					
BRAIN		(5) 5	(5) 5	(5) 5	(5) 5
NO ABNORMALITY DETECTED					

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 13 (Continued)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT	LESION INCIDENCE (Numeric)				
		0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII	
SPINAL CORD NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
STOMACH NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
DUODENUM NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
JEJUNUM NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
ILEUM NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
PANCREAS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
CECUM NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 13 (Continued)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	LESION INCIDENCE (Numeric)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
COLON NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
RECTUM NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
THYMUS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
ADRENAL GLANDS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
SCIATIC NERVE NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
THYROID GLAND NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 13 (Continued)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT	LESION INCIDENCE (Numeric)			
		0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
PARATHYROID GLANDS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
TRACHEA NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
ESOPHAGUS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
PHARYNX/LARYNX NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
EYE(S) NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
PROSTATE NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
SEMINAL VESICLES NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 13 (Continued)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT	LESION INCIDENCE (Numeric)				
		0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII	
URINARY BLADDER NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
TESTES NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
EPIDIDYIMIDES NO ABNORMALITY DETECTED		(5) 4	(5) 5	(5) 5	(5) 4	
DISCOLORATION, MOTTLED, TAIL, RIGHT. DISCOLORATION, TAN, FIRM, TAIL.		1			1	
STERNUM NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
NOSE NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 14
INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 25 SACRIFICE

LESIONS	LESION INCIDENCE (Numeric)				
	TREATMENT	0	25	125	600
		mg/m ³ I	mg/m ³ III	mg/m ³ V	mg/m ³ VII
LIVER		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
ESOPHAGUS		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
STOMACH		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
DUODENUM		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
JEJUNUM		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
ILEUM		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
CECUM		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
COLON		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 14 (Continued)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS

DAY 25 SACRIFICE

LESIONS	LESION INCIDENCE (Numeric)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
RECTUM		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
PANCREAS		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
URINARY BLADDER		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
KIDNEYS		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
PHARYNX/LARYNX		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
TRACHEA		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
LUNGS		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5
NOSE		(5)	(5)	(5)	(5)
NO ABNORMALITY DETECTED		5	5	5	5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 14 (Continued)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 25 SACRIFICE

LESIONS	TREATMENT	LESION INCIDENCE (Numeric)				
		0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII	
HEART NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
SPLEEN NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
THYMUS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
ADRENAL GLANDS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
PARATHYROID GLANDS NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
THYROID GLAND NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	
BRAIN NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5	

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 14 (Continued)

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS
DAY 25 SACRIFICE

LESIONS	LESION INCIDENCE (Numeric)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
SPINAL CORD NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
SCIATIC NERVE NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
STERNUM NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
EPIDIDYIMIDES NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
PROSTATE NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
SEMINAL VESICLES NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
TESTES NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5
EYE(S) NO ABNORMALITY DETECTED		(5) 5	(5) 5	(5) 5	(5) 5

Figures in parentheses is the number of animals grossly examined for this tissue
The absence of a number indicates the finding specified was not identified

TABLE 15

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC)				
		0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII	
DIGESTIVE SYSTEM						
LIVER						
INFLAMMATION, SUBACUTE/CHRONIC.		(5)	(5)	(5)	(5)	
minimal		5	5	5	5	
total observations per lesion		5	5	5	5	
INFLAMMATION, GRANULOMATOUS, with mineralization.						
minimal		1				
total observations per lesion		1				
FATTY CHANGE, MEDIAN CLEFT.						
minimal				1		
total observations per lesion				1		
PANCREAS						
NO ABNORMALITY DETECTED		(5)			(5)	
		5			5	
ESOPHAGUS						
NO ABNORMALITY DETECTED		(5)			(5)	
		5			5	
STOMACH						
NO ABNORMALITY DETECTED		(5)			(5)	
		5			5	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	LESION INCIDENCE (NUMERIC)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
DIGESTIVE SYSTEM					
DUODENUM		(5) 5			(5) 5
NO ABNORMALITY DETECTED					
JEJUNUM		(5) 5			(5) 5
NO ABNORMALITY DETECTED					
ILEUM		(5) 5			(5) 5
NO ABNORMALITY DETECTED					
CECUM		(5) 5			(5) 5
NO ABNORMALITY DETECTED					
COLON		(5) 5			(5) 5
NO ABNORMALITY DETECTED					
RECTUM		(5) 5			(5) 5
NO ABNORMALITY DETECTED					

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	LESION INCIDENCE (NUMERIC)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
URINARY SYSTEM					
KIDNEYS					
NO ABNORMALITY DETECTED		(5) 3	(5) 4	(5) 1	(5) 1
NEPHROPATHY, CHRONIC PROGRESSIVE. minimal		2		4	3
mild					1
total observations per lesion		2		4	4
HYDRONEPHROSIS, UNILATERAL. minimal			1 1		
total observations per lesion					
URINARY BLADDER					
NO ABNORMALITY DETECTED		(5) 5			(5) 5
RESPIRATORY SYSTEM					
LUNGS					
NO ABNORMALITY DETECTED		(5) 4	(5) 2	(5) 5	(5) 5
INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR. minimal			3 3	5 5	5 5
total observations per lesion					

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)
INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT					LESION INCIDENCE (NUMERIC)			
	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII					
RESPIRATORY SYSTEM									
LUNGS									
INFLAMMATION, SUBACUTE/CHRONIC, FOCAL. minimal	(5)	(5)	(5)	(5)					
total observations per lesion	1	2							
INFLAMMATION, ACUTE, PERIVASCULAR. minimal	1	2							
total observations per lesion		2							
HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL. minimal		2							
total observations per lesion			5	5					
TRACHEA									
NO ABNORMALITY DETECTED	(5)			(5)					
	5			5					
PHARYNX/LARYNX									
NO ABNORMALITY DETECTED	(5)	(5)	(5)	(5)					
NECROSIS, CARTILAGE. minimal	5	3	1						
total observations per lesion									
METAPLASIA, SQUAMOUS. minimal		2	4	4					

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT					LESION INCIDENCE (NUMERIC)				
	0	25	125	600		0	25	125	600	
	mg/m ³ I	mg/m ³ III	mg/m ³ V	mg/m ³ VII						
RESPIRATORY SYSTEM										
PHARYNX/LARYNX	(5)	(5)	(5)	(5)						
METAPLASIA, SQUAMOUS.		2	4	4						
total observations per lesion										
NOSE I & II	(5)	(5)	(5)	(5)						
NO ABNORMALITY DETECTED	5	5	5	2						
INFLAMMATION, SUBACUTE/CHRONIC.				1						
minimal				1						
total observations per lesion				1						
HYPERTROPHY, GOBLET CELL.				2						
minimal				2						
total observations per lesion				2						
HYPERPLASIA/HYPERTROPHY, RESPIRATORY.				2						
minimal				2						
total observations per lesion				2						
DEGENERATION/NECROSIS, OLFACTORY.				1						
minimal				1						
total observations per lesion				1						
NOSE III & IV	(5)	(5)	(5)	(5)						
NO ABNORMALITY DETECTED	5	1	1	1						

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT					LESION INCIDENCE (NUMERIC)				
						0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII	
RESPIRATORY SYSTEM										
NOSE III & IV						(5)	(5)	(5)	(5)	
HYPERTROPHY, GOBLET CELL.										
minimal							4	4	5	
total observations per lesion							4	4	5	
CARDIOVASCULAR SYSTEM										
HEART						(5)			(5)	
NO ABNORMALITY DETECTED						5			5	
LYMPHATIC AND HEMATOPOIETIC SYSTEM										
SPLEEN						(5)	(1)		(5)	
NO ABNORMALITY DETECTED						5	1		5	
THYMUS						(5)			(5)	
NO ABNORMALITY DETECTED						5			5	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT					LESION INCIDENCE (NUMERIC)				
	0	25	125	600		0	25	125	600	
	mg/m ³	mg/m ³	mg/m ³	mg/m ³		I	III	V	VII	
LYMPHATIC AND HEMATOPOIETIC SYSTEM										
MESENTERIC LYMPH NODE						(5)			(5)	
NO ABNORMALITY DETECTED						5			5	
BONE MARROW						(5)			(5)	
NO ABNORMALITY DETECTED						5			5	
ENDOCRINE SYSTEM										
THYROID GLAND						(5)			(5)	
NO ABNORMALITY DETECTED						5			5	
PARATHYROID GLANDS						(5)			(5)	
NO ABNORMALITY DETECTED						4			3	
NOT PRESENT.						1			2	
ADRENAL GLANDS						(5)			(5)	
NO ABNORMALITY DETECTED						3			5	
NOT PRESENT, MEDULLA.						2				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT					LESION INCIDENCE (NUMERIC)			
	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII					
NERVOUS SYSTEM									
BRAIN									
NO ABNORMALITY DETECTED	(5)							(5)	5
SPINAL CORD									
NO ABNORMALITY DETECTED	(5)							(5)	5
SCIATIC NERVE									
NO ABNORMALITY DETECTED	(5)							(5)	5
MUSCULAR AND SKELETAL SYSTEM									
STERNUM									
NO ABNORMALITY DETECTED	(5)							(5)	5
REPRODUCTIVE SYSTEM									
TESTES									
NO ABNORMALITY DETECTED	(5)	(5)	(5)	(5)				(5)	2

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC)				
		0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII	
REPRODUCTIVE SYSTEM						
TESTES			(5)	(5)	(5)	(5)
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL.						
minimal						2
mild						1
total observations per lesion						3
PROSTATE			(5)		(5)	(5)
NO ABNORMALITY DETECTED			4			5
INFLAMMATION, SUBACUTE/CHRONIC.						
minimal			1			
total observations per lesion			1			
EPIDIDYIMIDES			(5)		(5)	(5)
NO ABNORMALITY DETECTED			2			1
OLIGOSPERMIA/GERM CELL DEBRIS, UNILATERAL.						
minimal						1
total observations per lesion						1
OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL.						
minimal						3
mild						
total observations per lesion						3

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 15 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 11 SACRIFICE

LESIONS	LESION INCIDENCE (NUMERIC)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
REPRODUCTIVE SYSTEM					
EPIDIDYIMIDES		(5)			(5)
GRANULOMA, SPERM.		1			
SEMINAL VESICLES		(5)			(5)
NO ABNORMALITY DETECTED		5			5
SPECIAL SENSES SYSTEM					
EYE(S)		(5)			(5)
NO ABNORMALITY DETECTED		5			5

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 16

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 25 SACRIFICE

LESIONS	TREATMENT					LESION INCIDENCE (NUMERIC)				
	0	25	125	600		0	25	125	600	
	mg/m ³ I	mg/m ³ III	mg/m ³ V	mg/m ³ VII						
DIGESTIVE SYSTEM										
LIVER						(5)			(5)	
INFLAMMATION, SUBACUTE/CHRONIC.										
minimal						5			5	
total observations per lesion						5			5	
FATTY CHANGE, MEDIAN CLEFT.										
minimal						1			1	
mild						1			1	
total observations per lesion						2			1	
URINARY SYSTEM										
KIDNEYS						(5)			(5)	
NO ABNORMALITY DETECTED						1			1	
NEPHROPATHY, CHRONIC PROGRESSIVE.										
minimal						4			3	
total observations per lesion						4			3	
HYDRONEPHROSIS, UNILATERAL.										
minimal									1	
total observations per lesion									1	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 16 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 25 SACRIFICE

LESIONS	LESION INCIDENCE (NUMERIC)				
	TREATMENT	0 mg/m ³ I	25 mg/m ³ III	125 mg/m ³ V	600 mg/m ³ VII
RESPIRATORY SYSTEM					
LUNGS					
NO ABNORMALITY DETECTED		(5)	(5)	(5)	(5)
INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR.		4	5	3	4
. minimal				1	1
total observations per lesion				1	1
INFLAMMATION, SUBACUTE/CHRONIC, FOCAL.					
minimal		1		1	
total observations per lesion		1		1	
PHARYNX/LARYNX					
NO ABNORMALITY DETECTED		(5)	(5)	(5)	(5)
NECROSIS, CARTILAGE.		5	5	5	3
minimal					2
total observations per lesion					2
NOSE I & II					
NO ABNORMALITY DETECTED		(5)			(5)
		5			5
NOSE III & IV					
NO ABNORMALITY DETECTED		(5)			(5)
		5			5

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

TABLE 16 (Continued)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
DAY 25 SACRIFICE

LESIONS	TREATMENT					LESION INCIDENCE (NUMERIC)				
	mg/m ³					mg/m ³				
	I					III				
	V					V				
	VII					VII				
REPRODUCTIVE SYSTEM										
TESTES										
NO ABNORMALITY DETECTED						(5)				(5)
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, UNILATERAL.						4				5
minimal						1				
total observations per lesion						1				

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

FIGURES

FIGURE 1

SCHEMATIC OF EXPOSURE SYSTEM





FIGURE 2
MEAN BODY WEIGHTS OF MALE RATS



* Weight losses due to fasting of rats prior to clinical pathology evaluations.

APPENDICES

APPENDIX A

Daily Atmospheric Analyses

DAILY ATMOSPHERIC ANALYSES

EXPLANATORY NOTES

ABBREVIATIONS:

S.D. - standard deviation
n - number of samples
mg/m³ - milligrams per cubic meter

NOTES:

Values are reported to 2 significant figures.

DAILY ATMOSPHERIC ANALYSES

GROUP: I DESIGN CONCENTRATION: 0 mg/m³

EXPOSURE NUMBER	TEST DAY	MEASURED CONCENTRATION (mg/m ³)			
		MEAN	S.D.	RANGE	n
1	0	0	0	0	1
2	1	0	0	0	1
3	2	0	0	0	1
4	3	0	0	0	1
5	4	0	0	0	1
6	7	0	0	0	1
7	8	0	0	0	1
8	9	0	0	0	1
9	10	0	0	0	1

GROUP: III DESIGN CONCENTRATION: 25 mg/m³

EXPOSURE NUMBER	TEST DAY	MEASURED CONCENTRATION (mg/m ³)			
		MEAN	S.D.	RANGE	n
1	0	15	9.8	4.0 - 27	6
2	1	26	8.7	13 - 36	6
3	2	34	26	8.4 - 70	6
4	3	17	7.7	5.0 - 27	6
5	4	24	6.7	18 - 36	6
6	7	31	17	7.9 - 58	6
7	8	19	14	6.4 - 45	6
8	9	19	10	8.4 - 39	6
9	10	24	18	8.4 - 55	6

DAILY ATMOSPHERIC ANALYSES

GROUP: V DESIGN CONCENTRATION: 125 mg/m³

EXPOSURE NUMBER	TEST DAY	MEASURED CONCENTRATION (mg/m ³)			
		MEAN	S.D.	RANGE	n
1	0	120	22	110 - 170	6
2	1	99	41	50 - 160	6
3	2	140	46	62 - 200	6
4	3	110	25	94 - 160	6
5	4	120	34	73 - 160	6
6	7	120	37	80 - 170	6
7	8	110	17	94 - 140	6
8	9	79	36	18 - 120	6
9	10	96	12	84 - 110	6

GROUP: VII DESIGN CONCENTRATION: 600 mg/m³

EXPOSURE NUMBER	TEST DAY	MEASURED CONCENTRATION (mg/m ³)			
		MEAN	S.D.	RANGE	n
1	0	720	150	460 - 840	6
2	1	650	70	560 - 720	6
3	2	460	250	85 - 840	6
4	3	460	160	280 - 720	6
5	4	520	180	380 - 860	6
6	7	720	260	290 - 960	6
7	8	620	150	440 - 850	6
8	9	600	120	470 - 780	6
9	10	620	100	490 - 740	6

APPENDIX B

Daily Environmental Conditions

DAILY ENVIRONMENTAL CONDITIONS

EXPLANATORY NOTES

ABBREVIATIONS:

n - number of observations

NOTES:

Values are reported to 2 significant figures.

DAILY ENVIRONMENTAL CONDITIONS

GROUP: I DESIGN CONCENTRATION: 0 mg/m³

EXPOSURE NUMBER	TEST DAY	TEMPERATURE (°C)	n	RELATIVE HUMIDITY (%)	n	TOTAL AIRFLOW (L/MIN)	n
1	1	24 - 26	3	37 - 50	2	30	1
2	2	23 - 25	3	46 - 47	2	30	1
3	3	23 - 25	3	43 - 49	2	30	1
4	4	23 - 24	3	40 - 44	2	30	1
5	5	23 - 25	3	38 - 42	2	30	1
6	8	24 - 24	3	43 - 46	2	30	1
7	9	23 - 24	3	35 - 39	2	30	1
8	10	23 - 24	3	43 - 45	2	30	1
9	11	22 - 23	3	37 - 39	2	30	1

GROUP: III DESIGN CONCENTRATION: 25 mg/m³

EXPOSURE NUMBER	TEST DAY	TEMPERATURE (°C)	n	RELATIVE HUMIDITY (%)	n	TOTAL AIRFLOW (L/MIN)	n
1	1	24 - 26	3	42 - 54	2	30	1
2	2	23 - 24	3	46 - 51	2	30	2
3	3	22 - 24	3	51 - 54	2	30	1
4	4	22 - 23	3	40 - 41	2	30	1
5	5	24 - 24	3	41 - 51	2	30	2
6	8	24 - 24	3	40 - 50	2	30	1
7	9	23 - 24	3	40 - 42	2	30	1
8	10	23 - 24	3	39 - 43	2	30	1
9	11	22 - 24	3	38 - 42	2	30	1

DAILY ENVIRONMENTAL CONDITIONS

GROUP: V DESIGN CONCENTRATION: 125 mg/m³

EXPOSURE NUMBER	TEST DAY	TEMPERATURE (°C)	n	RELATIVE HUMIDITY (%)	n	TOTAL AIRFLOW (L/MIN)	n
1	1	23 - 25	3	50 - 61	2	30	1
2	2	22 - 24	3	54 - 56	2	30	1
3	3	22 - 23	3	56 - 58	2	30	1
4	4	22 - 23	3	50 - 54	2	30	1
5	5	23 - 23	3	53 - 57	2	30	1
6	8	23 - 24	3	48 - 57	2	30	1
7	9	22 - 23	3	48 - 58	2	30	1
8	10	22 - 24	3	37 - 43	2	30	1
9	11	22 - 23	3	39 - 41	2	30	1

GROUP: VII DESIGN CONCENTRATION: 600 mg/m³

EXPOSURE NUMBER	TEST DAY	TEMPERATURE (°C)	n	RELATIVE HUMIDITY (%)	n	TOTAL AIRFLOW (L/MIN)	n
1	1	23 - 24	3	69 - 81	2	30	1
2	2	21 - 23	3	71 - 73	2	30	1
3	3	21 - 22	3	72 - 78	2	30	1
4	4	21 - 22	3	65 - 70	2	30	1
5	5	21 - 22	3	75 - 78	2	30	1
6	8	21 - 22	3	70 - 72	2	30	1
7	9	21 - 22	3	72 - 76	2	30	1
8	10	21 - 22	3	77 - 82	2	30	1
9	11	22 - 22	3	82 - 84	2	30	1

APPENDIX C

Individual Body Weights

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

Individual Body Weights

	Individual Body Weights									
	Body Weight g	Day 0	Day 1	Day 2	Day 3	Day 4	Day 7	Day 8	Day 9	Day 10
Male, I - 0 mg/m ³										
637800	291.0	305.1	309.4	316.1	325.8	346.3	355.1	360.1	366.6	
637801	305.0	308.3	317.9	322.1	330.9	337.8	348.0	350.6	353.7	
637802	302.0	308.8	317.9	322.1	330.9	341.4	348.0	350.6	353.7	
637803	292.0	292.0	300.2	310.6	314.8	332.3	335.0	340.1	343.0	
637804	298.0	306.2	312.7	313.7	314.2	332.8	334.4	338.2	340.2	
637805	267.0	273.3	282.0	287.8	295.1	322.0	326.0	329.1	329.5	
637806	309.0	310.0	318.7	324.7	327.1	343.1	346.5	350.2	350.1	
637807	257.0	254.9	260.4	264.8	268.0	279.5	281.0	284.2	286.1	
637808	333.0	329.0	341.9	344.4	348.2	373.7	372.3	374.5	384.0	
637809	264.0	264.0	267.8	271.9	271.9	282.4	290.1	290.5	300.3	

Individual Body Weights

	Individual Body Weights				
	Body Weight g	Day 11	Day 14	Day 18	Day 25
Male, I - 0 mg/m ³					
637800	327.0	340.0	406.1	388.5	393.6
637801	303.0	355.0	409.7	393.6	320.6
637802	317.0	298.0	339.5	320.6	438.5
637803	313.0	394.0	449.8	438.5	337.8
637804	299.0	306.0	353.2	337.8	
637805	304.0	340.0	406.1	388.5	
637806	332.0	355.0	409.7	393.6	
637807	264.0	298.0	339.5	320.6	
637808	340.0	394.0	449.8	438.5	
637809	265.0	306.0	353.2	337.8	

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

Body Weight g	Individual Body Weights									
	Day 0		Day 1		Day 2		Day 3		Day 4	
	g	g	g	g	g	g	g	g	g	g
Male, III - 25 mg/m ³										
637810	296.0	296.8	296.8	297.1	298.0	297.1	301.9	329.1	326.8	331.5
637811	298.0	296.7	296.7	302.5	300.3	302.5	308.4	331.3	330.8	330.9
637812	303.0	299.7	299.7	303.0	300.8	303.0	308.8	335.0	337.2	339.7
637813	292.0	290.9	290.9	296.9	294.0	296.9	302.8	326.3	325.4	326.8
637814	295.0	285.3	285.3	288.7	283.9	288.7	292.0	309.0	308.6	312.0
637815	270.0	267.5	267.5	273.0	272.2	273.0	274.4	294.7	285.4	299.6
637816	305.0	298.9	298.9	298.4	299.6	298.4	301.4	321.5	325.1	324.1
637817	259.0	253.6	253.6	255.6	256.0	255.6	258.4	277.3	272.4	272.1
637818	301.0	290.0	290.0	298.0	293.0	298.0	305.0	319.2	322.0	321.0
637819	270.0	266.5	266.5	279.4	274.1	279.4	283.6	314.7	318.1	320.8

Body Weight g	Body Weight				
	Day 11		Day 14		Day 18
	g	g	g	g	g
Male, III - 25 mg/m ³					
637810	293.0	299.0	308.4	346.3	332.4
637811	298.0	337.0	368.7	384.1	370.0
637812	303.0	276.0	297.4	311.3	296.2
637813	291.0	323.0	344.8	369.7	357.4
637814	287.0	334.0	365.3	391.6	388.5
637815	273.0				
637816	302.0				
637817	243.0				
637818	285.0				
637819	293.0				

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

Male, V - 125 mg/m ³	Individual Body Weights																	
	Body Weight		Body Weight		Body Weight		Body Weight		Body Weight		Body Weight		Body Weight		Body Weight		Body Weight	
	g	Day 0	g	Day 1	g	Day 2	g	Day 3	g	Day 4	g	Day 7	g	Day 8	g	Day 9	g	Day 10
637820	301.0		288.2		286.8		300.9		308.3		330.1		328.4		320.2		321.5	
637821	294.0		281.9		283.3		288.4		291.9		315.4		304.6		303.1		299.8	
637822	302.0		289.8		296.3		296.1		298.4		319.4		320.4		314.0		318.1	
637823	290.0		287.7		291.2		294.3		295.7		321.7		322.6		317.4		321.7	
637824	292.0		287.7		282.1		293.4		290.9		310.9		312.4		307.0		311.8	
637825	294.0		286.6		288.1		296.4		295.3		323.1		317.0		311.1		317.1	
637826	316.0		307.3		310.2		311.8		316.6		346.1		332.7		336.8		344.0	
637827	277.0		271.0		271.0		281.6		282.8		304.8		301.4		298.4		299.9	
637828	300.0		297.7		302.7		310.8		313.4		330.0		326.0		326.1		324.7	
637829	289.0		281.6		289.0		293.7		298.2		327.4		325.1		324.0		328.6	

Male, V - 125 mg/m ³	Body Weight					Body Weight				
	Body Weight		Body Weight		Body Weight		Body Weight		Body Weight	
	g	Day 11	g	Day 14	g	Day 18	g	Day 22	g	Day 25
637820	288.0								364.9	
637821	264.0								405.4	
637822	282.0								349.2	
637823	290.0								385.9	
637824	277.0								391.2	
637825	290.0		326.0		377.1		360.0			
637826	320.0		356.0		419.7		394.1			
637827	276.0		315.0		359.4		336.5			
637828	293.0		344.0		397.0		368.6			
637829	291.0		345.0		405.6		375.1			

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

	Individual Body Weights									
	Body Weight g	Body Weight g	Body Weight g	Body Weight g	Body Weight g	Body Weight g	Body Weight g	Body Weight g	Body Weight g	Body Weight g
	Day 0	Day 1	Day 2	Day 3	Day 4	Day 7	Day 8	Day 9	Day 10	
Male, VII - 600 mg/m ³										
637830	295.0	284.7	289.7	285.0	276.7	306.1	306.0	302.5	308.0	
637831	293.0	280.6	285.1	291.3	282.6	310.1	305.8	308.1	306.2	
637832	315.0	290.0	298.9	295.9	294.2	328.8	322.5	330.2	315.5	
637833	308.0	294.2	293.9	294.8	296.9	332.7	327.3	329.9	332.4	
637834	302.0	286.2	278.7	278.1	287.8	314.0	307.1	302.2	307.0	
637835	292.0	276.3	271.0	266.7	275.1	293.8	293.0	291.0	291.4	
637836	311.0	300.9	305.1	304.2	309.4	329.9	328.9	325.3	326.6	
637837	261.0	247.8	248.6	242.7	243.4	267.9	257.3	260.9	257.2	
637838	322.0	318.3	318.4	319.0	326.5	345.9	346.3	347.0	351.2	
637839	286.0	281.6	281.3	281.6	281.2	303.1	296.8	299.7	294.1	

	Individual Body Weights				
	Body Weight g	Body Weight g	Body Weight g	Body Weight g	Body Weight g
	Day 11	Day 14	Day 18	Day 22	Day 25
Male, VII - 600 mg/m ³					
637830	264.0				
637831	270.0				
637832	283.0				
637833	290.0				
637834	275.0				
637835	257.0	296.0	330.9	358.7	345.5
637836	295.0	334.0	370.6	393.6	384.6
637837	226.0	263.0	285.3	299.7	291.1
637838	304.0	360.0	400.7	422.6	413.8
637839	258.0	300.0	327.5	343.1	335.0

APPENDIX D

Individual Clinical Observations and Mortality Records

Individual Clinical Observations and Mortality Records

Sex	Group	Animal	Observation	Days
M	I	637800	General observation, No Abnormality Detected	0-11
			Eye Observations, Bled via Orbital for Clin Path, Left	11
			Sacrificed by design	11
M	I	637801	General observation, No Abnormality Detected	0-11
			Eye Observations, Bled via Orbital for Clin Path, Left	11
			Sacrificed by design	11
M	I	637802	General observation, No Abnormality Detected	0-11
			Eye Observations, Bled via Orbital for Clin Path, Left	11
			Sacrificed by design	11
M	I	637803	General observation, No Abnormality Detected	0-11
			Eye Observations, Bled via Orbital for Clin Path, Left	11
			Sacrificed by design	11
M	I	637804	General observation, No Abnormality Detected	0-11
			Eye Observations, Bled via Orbital for Clin Path, Bilateral	11
			Sacrificed by design	11
M	I	637805	General observation, No Abnormality Detected	0-25
			Eye Observations, Bled via Orbital for Clin Path, Left	11,25
			Sacrificed by design	25
M	I	637806	General observation, No Abnormality Detected	0-25
			Eye Observations, Bled via Orbital for Clin Path, Left	11,25
			Sacrificed by design	25
M	I	637807	General observation, No Abnormality Detected	0-25
			Eye Observations, Bled via Orbital for Clin Path, Left	11,25
			Sacrificed by design	25
M	I	637808	General observation, No Abnormality Detected	0-25
			Eye Observations, Bled via Orbital for Clin Path, Left	11,25
			Sacrificed by design	25
M	I	637809	General observation, No Abnormality Detected	0-25
			Eye Observations, Bled via Orbital for Clin Path, Left	11,25
			Sacrificed by design	25

Individual Clinical Observations and Mortality Records

Sex	Group	Animal	Observation	Days
M	III	637810	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	III	637811	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	III	637812	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	III	637813	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	III	637814	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	III	637815	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Hair Loss, Face, Right Wound, Superficial, Face Sacrificed by design	0,11-25 11,25 8-10 1-7 25
M	III	637816	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	III	637817	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	III	637818	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	III	637819	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25

Individual Clinical Observations and Mortality Records

Sex	Group	Animal	Observation	Days
M	V	637820	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	V	637821	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	V	637822	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Hair Loss, Forepaw, Bilateral Hair Loss, Forepaw, Left Sacrificed by design	0-4,11 11 8-10 7 11
M	V	637823	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Hair Loss, Forelimb, Bilateral Hair Loss, Forepaw, Bilateral Sacrificed by design	0-1,11 11 4-10 2-10 11
M	V	637824	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	V	637825	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	V	637826	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	V	637827	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	V	637828	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	V	637829	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25

Individual Clinical Observations and Mortality Records

Sex	Group	Animal	Observation	Days
M	VII	637830	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	VII	637831	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	VII	637832	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	VII	637833	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	VII	637834	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-11 11 11
M	VII	637835	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	VII	637836	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	VII	637837	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	VII	637838	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25
M	VII	637839	General observation, No Abnormality Detected Eye Observations, Bled via Orbital for Clin Path, Left Sacrificed by design	0-25 11,25 25

APPENDIX E

Individual Animal Clinical Pathology Data

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

EXPLANATORY NOTES

ABBREVIATIONS:

General:

ADEQ - adequate
DECR - decreased
NSR - no sample received for testing
NT - not taken or not performed
OK - sample condition OK for testing
RNV - result not valid
UTD - unable to determine
< - less than

Individual Hematology Values:

COND - sample condition
RBC - red blood cell count
HGB - hemoglobin
HCT - hematocrit
MCV - mean corpuscular volume
MCH - mean corpuscular hemoglobin
MCHC - mean corpuscular hemoglobin concentration
RDW - red cell distribution width
ARET - absolute reticulocyte count
NRBC - nucleated red blood cell count
WBC - white blood cell count
ANEU - absolute neutrophil (all forms)
ANPR - absolute neutrophil precursor
ALYM - absolute lymphocyte
AMON - absolute monocyte
AEOS - absolute eosinophil
ABAS - absolute basophil
ALUC - absolute large unstained cell
ABLT - absolute blast leukocyte
AMSC - absolute miscellaneous leukocyte
PLT - platelet count
BASO - percent basophil
BLST - percent blast leukocyte
EOS - percent eosinophil
LUC - percent large unstained cell
LYMP - percent lymphocyte
MISC - percent miscellaneous leukocyte
MONO - percent monocyte
NEUT - percent neutrophil
NPRE - percent neutrophil precursor

Individual Red Blood Cell Morphology Values:

NORM - normal
ANIS - anisocytosis
MICR - microcytes
MACR - macrocytes
POLY - polychromasia
HYPO - hypochromasia
ECHI - echinocytes
ACAN - acanthocytes
TARG - target cells
RX - rouleaux
HJB - Howell-Jolly body
-- - not observed or not examined; see whole blood sample condition

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

EXPLANATORY NOTES (Continued)

ABBREVIATIONS: (Continued)

Individual White Blood Cell / Platelet Morphology Values:

NORM - normal
SM - smudge white blood cells
TG - toxic granulation (white blood cells)
DB - Döhle bodies
VN - vacuolated neutrophils
PC - platelet clumps
GP - giant platelets
BP - bizarre platelets
-- - not observed or not examined; see whole blood sample condition

Individual Coagulation Values:

PHEM - plasma hemolysis
PLIP - plasma lipemia
PICT - plasma icterus
PT - prothrombin time
APTT - activated partial thromboplastin time

Individual Serum Chemistry Values:

SHEM - serum hemolysis
SLIP - serum lipemia
SICT - serum icterus
AST - aspartate aminotransferase
ALT - alanine aminotransferase
SDH - sorbitol dehydrogenase
ALKP - alkaline phosphatase
BILI - total bilirubin
BUN - urea nitrogen
CREA - creatinine
CHOL - cholesterol
TRIG - triglycerides
GLUC - glucose
TP - total protein
ALB - albumin
GLOB - globulin
CALC - calcium
IPHS - inorganic phosphorous
NA - sodium
K - potassium
CL - chloride
PFLU - plasma fluoride
FHEM - plasma hemolysis from blood sample for fluoride determination
FLIP - plasma lipemia from blood sample for fluoride determination
FICT - plasma icterus from blood sample for fluoride determination

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

EXPLANATORY NOTES (Continued)

ABBREVIATIONS: (Continued)

Individual Urinalysis Values:

QUAL - quality (modifies color)
COL - color
CLAR - clarity
VOL - volume
UOSM - urine osmolality
SG - specific gravity
pH - the logarithm of the reciprocal of the hydrogen ion concentration
UPRO - urine protein
UGLU - urine glucose
KET - ketone
UBIL - urine bilirubin
BLD - blood
URO - urobilinogen
UFLU - urine fluoride

Individual Urine Microscopic Examination Values:

EPIT - epithelial cells
UWBC - urine white blood cells
URBC - urine red blood cells
NCRY - normal crystals
MICR - microorganisms

INDIVIDUAL ANIMAL CLINICAL PATHOLOGY DATA

EXPLANATORY NOTES (Continued)

KEY:

Red Blood Cell Morphology Values, White Blood Cell / Platelet Morphology Values, and Special Observations:

- 1 - few
- 2 - moderate
- 3 - many
- 4 - all

NOTES:

When individual animal data are not reported, it may be due to one of the following reasons or other reasons, all of which are explained in the study records:

- the sample was clotted (for hematology or coagulation data) (CLOT)
- there was insufficient sample for analysis
- a valid result could not be obtained (RNV)
- the sample was not suitable for evaluation
- the animal died prior to sample collection
- no sample was available for analysis (NSR)

When an individual observation is recorded as being less than a certain value, calculations are performed on half the recorded value. For example, if bilirubin is reported as <0.1, 0.05 is used for any calculations performed with that bilirubin data.

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	COND	RBC x10 ⁶ /μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x10 ³ /μL	NRBC /100 WBC	WBC x10 ³ /μL
Male, Group: I - 0 mg/m ³ - Day 11											
637800	OK	7.40	14.5	46.6	63.0	19.6	31.1	13.0	262.5	NT	16.07
637801	OK	7.34	14.3	44.6	60.8	19.5	32.0	13.2	199.1	NT	12.02
637802	OK	7.70	15.9	50.1	65.1	20.6	31.7	12.3	231.6	NT	11.19
637803	OK	7.51	14.8	46.6	62.0	19.7	31.8	12.7	239.0	NT	13.19
637804	OK	7.91	16.1	50.5	63.8	20.4	31.9	12.5	212.0	NT	14.93
637805	OK	7.51	15.2	47.2	62.8	20.2	32.2	13.4	298.4	NT	17.83
637806	OK	7.51	15.0	46.5	61.9	20.0	32.3	14.2	216.2	NT	10.06
637807	OK	7.81	15.4	47.5	60.8	19.7	32.4	12.6	204.9	NT	11.89
637808	OK	6.96	14.6	44.4	63.8	21.0	32.9	13.6	257.0	NT	14.14
637809	OK	8.08	16.0	48.5	60.0	19.8	33.0	12.6	228.2	NT	9.77
Male, Group: III - 25 mg/m ³ - Day 11											
637810	OK	7.44	15.6	49.3	66.3	21.0	31.6	13.3	193.4	NT	12.43
637811	OK	7.47	14.7	45.9	61.5	19.7	32.0	13.3	176.7	NT	9.51
637812	OK	7.08	14.5	44.0	62.1	20.5	33.0	13.1	217.5	NT	10.48
637813	OK	7.21	14.5	45.1	62.6	20.1	32.1	13.4	189.4	NT	11.74
637814	OK	7.14	14.3	43.6	61.0	20.0	32.8	13.7	194.0	NT	11.73
637815	OK	8.74	16.6	51.5	58.9	19.0	32.2	11.8	250.7	NT	11.82
637816	OK	7.89	14.9	46.8	59.3	18.9	31.8	13.4	213.6	NT	20.28
637817	OK	8.68	16.5	52.5	60.5	19.0	31.4	12.7	178.5	NT	13.46
637818	OK	8.33	16.0	50.0	60.0	19.2	32.0	12.8	171.8	NT	13.88
637819	OK	7.37	14.3	45.0	61.1	19.4	31.8	13.7	251.3	0	12.40

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	COND	RBC x10 ⁶ /μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x10 ³ /μL	NRBC /100 WBC	WBC x10 ³ /μL
Male, Group: V - 125 mg/m ³ - Day 11											
637820	OK	7.46	15.1	47.0	63.0	20.2	32.1	14.5	207.0	NT	12.76
637821	OK	7.86	14.7	46.1	58.6	18.7	31.9	14.0	132.6	0	12.51
637822	OK	7.70	15.4	47.3	61.4	20.0	32.6	13.5	187.7	NT	14.60
637823	OK	7.57	15.1	46.8	61.8	19.9	32.3	12.8	161.5	0	11.14
637824	OK	8.31	15.8	50.1	60.3	19.0	31.5	12.1	119.8	NT	10.58
637825	OK	7.73	15.8	48.2	62.3	20.4	32.8	12.8	189.5	NT	11.74
637826	OK	6.96	14.6	45.2	64.9	21.0	32.3	13.4	167.6	NT	14.70
637827	OK	7.57	15.5	47.0	62.1	20.5	33.0	13.3	203.6	NT	13.16
637828	OK	7.33	15.6	47.2	64.4	21.3	33.0	13.5	160.4	NT	11.92
637829	OK	7.55	15.5	46.5	61.6	20.5	33.3	14.0	211.2	NT	10.05
Male, Group: VII - 600 mg/m ³ - Day 11											
637830	OK	8.72	17.0	51.4	58.9	19.5	33.1	14.0	202.4	0	11.31
637831	OK	8.01	16.2	49.5	61.8	20.2	32.7	13.7	132.5	NT	10.10
637832	OK	8.23	16.0	50.9	61.8	19.4	31.5	12.8	171.2	NT	16.11
637833	OK	7.67	15.2	47.0	61.3	19.8	32.3	12.6	157.2	NT	7.63
637834	OK	8.26	16.0	50.3	60.9	19.4	31.8	13.2	206.9	NT	15.32
637835	OK	7.91	15.5	47.4	59.9	19.6	32.7	13.7	153.6	0	10.58
637836	OK	7.68	15.4	48.1	62.6	20.1	32.0	14.3	168.6	NT	19.39
637837	OK	8.83	16.9	52.0	58.9	19.1	32.5	13.5	82.6	NT	20.03
637838	OK	7.18	15.0	46.2	64.4	20.9	32.4	13.1	167.3	NT	8.09
637839	OK	8.05	15.8	49.2	61.1	19.6	32.1	13.9	154.0	NT	11.94

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	ANEU x10 ³ /μL	ANPR x10 ³ /μL	ALYM x10 ³ /μL	AMON x10 ³ /μL	AEOS x10 ³ /μL	ABAS x10 ³ /μL	ALUC x10 ³ /μL	ABLT x10 ³ /μL	AMSC x10 ³ /μL	PLT x10 ³ /μL	BASO %
Male, Group: I - 0 mg/m ³ - Day 11											
637800	2.15	NT	12.92	0.50	0.18	0.08	0.26	NT	NT	RNV	0.5
637801	2.01	NT	9.17	0.46	0.14	0.05	0.19	NT	NT	941	0.4
637802	1.24	NT	9.21	0.41	0.07	0.07	0.18	NT	NT	RNV	0.6
637803	3.32	NT	9.00	0.40	0.08	0.09	0.30	NT	NT	1187	0.7
637804	1.85	NT	12.47	0.36	0.07	0.04	0.13	NT	NT	RNV	0.3
637805	3.80	NT	13.00	0.45	0.12	0.14	0.30	NT	NT	1221	0.8
637806	1.18	NT	8.32	0.16	0.07	0.11	0.22	NT	NT	827	1.1
637807	1.68	NT	9.62	0.25	0.17	0.05	0.12	NT	NT	1126	0.4
637808	1.97	NT	11.35	0.38	0.16	0.06	0.23	NT	NT	1104	0.4
637809	1.69	NT	7.30	0.36	0.12	0.07	0.22	NT	NT	1171	0.7
Male, Group: III - 25 mg/m ³ - Day 11											
637810	0.98	NT	10.79	0.26	0.12	0.06	0.20	NT	NT	1034	0.5
637811	1.01	NT	7.90	0.24	0.06	0.10	0.20	NT	NT	919	1.0
637812	1.40	NT	8.63	0.16	0.10	0.04	0.14	NT	NT	840	0.4
637813	0.93	NT	10.14	0.22	0.07	0.12	0.26	NT	NT	1079	1.0
637814	1.82	NT	9.02	0.31	0.16	0.09	0.33	NT	NT	1008	0.8
637815	1.39	NT	9.34	0.37	0.09	0.20	0.43	NT	NT	RNV	1.7
637816	2.05	NT	17.04	0.59	0.10	0.12	0.39	NT	NT	1106	0.6
637817	1.01	NT	11.76	0.36	0.08	0.05	0.19	NT	NT	707	0.4
637818	0.94	NT	11.95	0.37	0.19	0.12	0.29	NT	NT	722	0.9
637819	2.23	0.00	9.92	0.00	0.12	0.00	0.00	0.00	0.12	860	0.0

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	ANEU x10 ³ /μL	ANPR x10 ³ /μL	ALYM x10 ³ /μL	AMON x10 ³ /μL	AEOS x10 ³ /μL	ABAS x10 ³ /μL	ALUC x10 ³ /μL	ABLT x10 ³ /μL	AMSC x10 ³ /μL	PLT x10 ³ /μL	BASO %
Male, Group: V - 125 mg/m ³ - Day 11											
637820	1.12	NT	10.77	0.47	0.18	0.03	0.19	NT	NT	858	0.2
637821	1.13	0.00	10.76	0.25	0.00	0.00	0.00	0.00	0.38	1061	0.0
637822	1.74	NT	12.02	0.39	0.20	0.04	0.20	NT	NT	1113	0.3
637823	1.23	0.00	9.58	0.00	0.11	0.00	0.00	0.00	0.22	740	0.0
637824	1.09	NT	8.69	0.41	0.14	0.04	0.21	NT	NT	841	0.4
637825	0.83	NT	10.17	0.35	0.06	0.09	0.23	NT	NT	965	0.8
637826	1.41	NT	12.26	0.46	0.19	0.10	0.29	NT	NT	903	0.7
637827	1.59	NT	10.86	0.26	0.17	0.05	0.21	NT	NT	988	0.4
637828	1.36	NT	9.04	0.49	0.83	0.04	0.18	NT	NT	RNV	0.3
637829	1.19	NT	8.11	0.41	0.09	0.05	0.20	NT	NT	1042	0.5
Male, Group: VII - 600 mg/m ³ - Day 11											
637830	1.58	0.00	9.05	0.00	0.11	0.00	0.00	0.00	0.57	RNV	0.0
637831	1.50	NT	7.91	0.31	0.10	0.07	0.20	NT	NT	867	0.7
637832	1.47	NT	13.95	0.31	0.13	0.08	0.18	NT	NT	841	0.5
637833	1.40	NT	5.66	0.25	0.11	0.05	0.16	NT	NT	954	0.6
637834	1.93	NT	12.29	0.55	0.20	0.06	0.31	NT	NT	1074	0.4
637835	1.16	0.00	9.10	0.00	0.32	0.00	0.00	0.00	0.00	893	0.0
637836	3.66	NT	14.62	0.54	0.12	0.14	0.29	NT	NT	778	0.7
637837	1.54	NT	16.67	0.74	0.18	0.14	0.76	NT	NT	980	0.7
637838	0.91	NT	6.64	0.20	0.02	0.07	0.23	NT	NT	1040	0.9
637839	1.49	NT	9.42	0.57	0.17	0.04	0.25	NT	NT	905	0.3

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	BLST %	EOS %	LUC %	LYMP %	MISC %	MONO %	NEUT %	NPPE %	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 11									
637800	NT	1.1	1.6	80.4	NT	3.1	13.4	NT	
637801	NT	1.2	1.6	76.3	NT	3.8	16.7	NT	
637802	NT	0.6	1.6	82.3	NT	3.7	11.1	NT	
637803	NT	0.6	2.3	68.2	NT	3.0	25.2	NT	
637804	NT	0.5	0.9	83.5	NT	2.4	12.4	NT	
637805	NT	0.7	1.7	72.9	NT	2.5	21.3	NT	
637806	NT	0.7	2.2	82.7	NT	1.6	11.7	NT	
637807	NT	1.4	1.0	80.9	NT	2.1	14.1	NT	
637808	NT	1.1	1.6	80.3	NT	2.7	13.9	NT	
637809	NT	1.2	2.3	74.7	NT	3.7	17.3	NT	
Male, Group: III - 25 mg/m ³ - Day 11									
637810	NT	1.0	1.6	86.8	NT	2.1	7.9	NT	
637811	NT	0.6	2.1	83.1	NT	2.5	10.6	NT	
637812	NT	1.0	1.3	82.3	NT	1.5	13.4	NT	
637813	NT	0.6	2.2	86.4	NT	1.9	7.9	NT	
637814	NT	1.4	2.8	76.9	NT	2.6	15.5	NT	
637815	NT	0.8	3.6	79.0	NT	3.1	11.8	NT	
637816	NT	0.5	1.9	84.0	NT	2.9	10.1	NT	
637817	NT	0.6	1.4	87.4	NT	2.7	7.5	NT	
637818	NT	1.4	2.1	86.1	NT	2.7	6.8	NT	
637819	0	1.0	0.0	80.0	1	0.0	18.0	0	1%-ATYPICAL LYMPHOCYTE

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	BLST %	EOS %	LUC %	LYMP %	MISC %	MONO %	NEUT %	NPRE %	SPECIAL OBSERVATIONS
Male, Group: V - 125 mg/m ³ - Day 11									
637820	NT	1.4	1.5	84.4	NT	3.7	8.8	NT	3%- ATYPICAL LYMPHOCYTE
637821	0	0.0	0.0	86.0	3	2.0	9.0	0	
637822	NT	1.4	1.4	82.3	NT	2.7	11.9	NT	
637823	0	1.0	0.0	86.0	2	0.0	11.0	0	2%- ATYPICAL LYMPHOCYTE
637824	NT	1.3	2.0	82.1	NT	3.9	10.3	NT	
637825	NT	0.5	2.0	86.6	NT	3.0	7.1	NT	
637826	NT	1.3	2.0	83.4	NT	3.1	9.6	NT	
637827	NT	1.3	1.6	82.5	NT	2.0	12.1	NT	
637828	NT	7.0	1.5	75.8	NT	4.1	11.4	NT	
637829	NT	0.9	2.0	80.7	NT	4.1	11.8	NT	
Male, Group: VII - 600 mg/m ³ - Day 11									
637830	0	1.0	0.0	80.0	5	0.0	14.0	0	5%-HYPERSEGMENTED NEUTROPHILS
637831	NT	1.0	2.0	78.3	NT	3.1	14.9	NT	
637832	NT	0.8	1.1	86.6	NT	1.9	9.1	NT	
637833	NT	1.4	2.1	74.2	NT	3.3	18.4	NT	
637834	NT	1.3	2.0	80.2	NT	3.6	12.6	NT	
637835	0	3.0	0.0	86.0	0	0.0	11.0	0	
637836	NT	0.6	1.5	75.4	NT	2.8	18.9	NT	
637837	NT	0.9	3.8	83.2	NT	3.7	7.7	NT	
637838	NT	0.3	2.9	82.1	NT	2.5	11.3	NT	
637839	NT	1.4	2.1	78.9	NT	4.8	12.5	NT	

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	COND	RBC x10 ⁶ /μL	HGB g/dL	HCT %	MCV fL	MCH pg	MCHC g/dL	RDW %	ARET x10 ³ /μL	NRBC /100 WBC	WBC x10 ³ /μL
Male, Group: I - 0 mg/m ³ - Day 25											
637805	OK	8.09	16.0	48.8	60.3	19.8	32.8	13.9	308.5	NT	23.02
637806	OK	8.22	15.6	48.7	59.2	19.0	32.1	13.7	235.4	NT	12.37
637807	OK	8.51	16.2	49.8	58.5	19.0	32.5	13.3	242.0	NT	9.91
637808	OK	7.43	15.1	45.2	60.9	20.3	33.4	12.6	258.8	NT	16.39
637809	OK	8.37	16.0	48.5	57.9	19.1	33.0	12.9	262.2	NT	11.73
Male, Group: III - 25 mg/m ³ - Day 25											
637815	OK	8.79	16.5	51.2	58.2	18.8	32.3	13.1	279.5	NT	10.88
637816	OK	8.54	15.7	49.4	57.9	18.4	31.8	13.4	249.1	NT	21.09
637817	OK	8.65	16.4	50.4	58.3	19.0	32.5	13.1	266.4	NT	11.95
637818	OK	8.58	15.6	49.7	57.9	18.2	31.4	13.2	271.7	NT	16.97
637819	OK	7.97	15.1	46.8	58.7	18.9	32.3	13.6	264.4	NT	13.65
Male, Group: V - 125 mg/m ³ - Day 25											
637825	OK	7.91	15.7	47.3	59.8	19.8	33.2	13.0	219.8	NT	13.01
637826	OK	7.34	14.8	45.1	61.5	20.2	32.8	13.0	238.8	NT	16.78
637827	OK	7.97	15.6	48.1	60.3	19.6	32.5	13.4	267.8	NT	18.42
637828	OK	7.35	15.5	47.3	64.3	21.1	32.8	13.1	261.1	NT	13.49
637829	OK	7.77	15.5	48.3	62.1	19.9	32.1	13.6	303.3	NT	10.19
Male, Group: VII - 600 mg/m ³ - Day 25											
637835	OK	8.19	15.5	48.2	58.8	18.9	32.2	13.7	267.3	NT	12.95
637836	OK	8.10	15.7	47.5	58.6	19.4	33.1	14.2	300.8	NT	17.98
637837	OK	8.41	15.5	48.4	57.6	18.4	32.0	13.8	209.9	NT	16.70
637838	OK	7.41	15.2	46.8	63.1	20.5	32.5	13.0	260.3	NT	12.60
637839	OK	8.13	15.5	47.6	58.6	19.1	32.5	13.4	227.7	NT	12.11

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	ANEU x10 ³ /μL	ANPR x10 ³ /μL	ALYM x10 ³ /μL	AMON x10 ³ /μL	AEOS x10 ³ /μL	ABAS x10 ³ /μL	ALUC x10 ³ /μL	ABLT x10 ³ /μL	AMSC x10 ³ /μL	PLT x10 ³ /μL	BASO %
Male, Group: I - 0 mg/m ³ - Day 25											
637805	4.81	NT	16.94	0.62	0.21	0.12	0.32	NT	NT	1011	0.5
637806	1.62	NT	9.93	0.33	0.11	0.10	0.27	NT	NT	RNV	0.8
637807	1.72	NT	7.70	0.19	0.13	0.03	0.14	NT	NT	1182	0.3
637808	2.84	NT	12.92	0.26	0.11	0.08	0.20	NT	NT	1164	0.5
637809	2.24	NT	8.68	0.34	0.16	0.12	0.20	NT	NT	995	1.0
Male, Group: III - 25 mg/m ³ - Day 25											
637815	2.14	NT	8.07	0.35	0.07	0.04	0.20	NT	NT	RNV	0.4
637816	3.65	NT	15.99	0.53	0.17	0.19	0.59	NT	NT	1057	0.9
637817	2.31	NT	8.91	0.35	0.13	0.07	0.17	NT	NT	840	0.6
637818	2.05	NT	13.92	0.41	0.14	0.12	0.34	NT	NT	941	0.7
637819	2.20	NT	10.51	0.49	0.25	0.05	0.16	NT	NT	RNV	0.4
Male, Group: V - 125 mg/m ³ - Day 25											
637825	1.37	NT	10.84	0.40	0.09	0.07	0.25	NT	NT	1000	0.5
637826	2.55	NT	13.52	0.23	0.10	0.08	0.29	NT	NT	879	0.5
637827	2.21	NT	15.09	0.42	0.13	0.15	0.39	NT	NT	1047	0.8
637828	1.74	NT	10.83	0.49	0.11	0.07	0.26	NT	NT	924	0.5
637829	0.99	NT	8.49	0.32	0.06	0.08	0.24	NT	NT	1170	0.8
Male, Group: VII - 600 mg/m ³ - Day 25											
637835	1.85	NT	10.32	0.35	0.16	0.08	0.19	NT	NT	851	0.6
637836	2.50	NT	14.49	0.43	0.11	0.11	0.32	NT	NT	880	0.6
637837	1.75	NT	13.86	0.35	0.10	0.12	0.52	NT	NT	979	0.7
637838	1.95	NT	9.93	0.39	0.05	0.06	0.21	NT	NT	1075	0.5
637839	1.95	NT	9.36	0.36	0.06	0.10	0.29	NT	NT	930	0.8

INDIVIDUAL HEMATOLOGY VALUES FOR MALE RATS

Animal Number	BLST %	EOS %	LUC %	LYMP %	MISC %	MONO %	NEUT %	NPRE %	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 25									
637805	NT	0.9	1.4	73.6	NT	2.7	20.9	NT	
637806	NT	0.9	2.2	80.3	NT	2.7	13.1	NT	
637807	NT	1.3	1.4	77.7	NT	1.9	17.4	NT	
637808	NT	0.7	1.2	78.8	NT	1.6	17.3	NT	
637809	NT	1.4	1.7	74.0	NT	2.9	19.1	NT	
Male, Group: III - 25 mg/m ³ - Day 25									
637815	NT	0.6	1.8	74.2	NT	3.2	19.7	NT	
637816	NT	0.8	2.8	75.8	NT	2.5	17.3	NT	
637817	NT	1.1	1.4	74.6	NT	2.9	19.3	NT	
637818	NT	0.8	2.0	82.0	NT	2.4	12.1	NT	
637819	NT	1.8	1.2	77.0	NT	3.6	16.1	NT	
Male, Group: V - 125 mg/m ³ - Day 25									
637825	NT	0.7	1.9	83.3	NT	3.1	10.5	NT	
637826	NT	0.6	1.7	80.6	NT	1.4	15.2	NT	
637827	NT	0.7	2.1	81.9	NT	2.3	12.0	NT	
637828	NT	0.8	1.9	80.3	NT	3.6	12.9	NT	
637829	NT	0.6	2.4	83.3	NT	3.1	9.7	NT	
Male, Group: VII - 600 mg/m ³ - Day 25									
637835	NT	1.2	1.5	79.7	NT	2.7	14.3	NT	
637836	NT	0.6	1.8	80.6	NT	2.4	13.9	NT	
637837	NT	0.6	3.1	83.0	NT	2.1	10.5	NT	
637838	NT	0.4	1.7	78.8	NT	3.1	15.5	NT	
637839	NT	0.5	2.4	77.3	NT	3.0	16.1	NT	

INDIVIDUAL RED BLOOD CELL MORPHOLOGY VALUES FOR MALE RATS

Animal Number	NORM	ANIS	MICR	MACR	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group: I - 0 mg/m ³ - Day 11											
637800	--	--	--	--	--	--	2	1	--	--	--
637801	--	--	--	--	--	--	2	1	--	--	--
637802	--	--	--	--	--	--	1	--	--	--	--
637803	NORMAL	--	--	--	--	--	--	--	--	--	--
637804	--	1	1	--	--	--	2	1	--	--	--
637805	--	--	--	--	--	--	2	1	--	--	--
637806	--	--	--	--	--	--	1	1	--	--	--
637807	--	--	--	--	--	--	1	--	--	--	--
637808	NORMAL	--	--	--	--	--	--	--	--	--	--
637809	--	--	--	--	--	--	1	1	--	--	--
Male, Group: III - 25 mg/m ³ - Day 11											
637810	--	--	--	--	--	--	4	--	--	--	--
637811	--	1	1	--	--	--	2	1	--	--	--
637812	--	--	--	--	--	--	1	--	--	--	--
637813	--	1	1	--	--	--	2	1	--	--	--
637814	--	--	--	--	--	--	2	1	--	--	--
637815	NORMAL	--	--	--	--	--	--	--	--	--	--
637816	--	--	--	--	--	--	--	1	--	--	--
637817	NORMAL	--	--	--	--	--	--	--	--	--	--
637818	NORMAL	--	--	--	--	--	--	--	--	--	--
637819	--	--	--	--	--	--	2	1	--	--	--

INDIVIDUAL RED BLOOD CELL MORPHOLOGY VALUES FOR MALE RATS

Animal Number	NORM	ANIS	MICR	MACR	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group: V - 125 mg/m ³ - Day 11											
637820	--	--	--	--	--	--	2	2	--	--	--
637821	--	1	1	--	--	--	1	1	--	--	--
637822	--	--	--	--	--	--	1	1	--	--	--
637823	--	--	--	--	--	--	1	1	--	--	--
637824	--	--	--	--	--	--	2	1	--	--	--
637825	--	--	--	--	--	--	2	1	--	--	--
637826	--	--	--	--	--	--	1	1	--	--	--
637827	--	--	--	--	--	--	3	1	--	--	--
637828	--	1	1	--	--	--	1	1	--	--	--
637829	--	1	1	--	--	--	1	--	--	--	--
Male, Group: VII - 600 mg/m ³ - Day 11											
637830	--	--	--	--	--	--	2	2	--	--	--
637831	--	--	--	--	--	--	1	--	--	--	--
637832	--	--	--	--	--	--	2	1	--	--	--
637833	NORMAL	--	--	--	--	--	--	--	--	--	--
637834	--	--	--	--	--	--	2	1	--	--	--
637835	NORMAL	--	--	--	--	--	--	--	--	--	--
637836	--	--	--	--	--	--	--	1	--	--	--
637837	NORMAL	--	--	--	--	--	--	--	--	--	--
637838	NORMAL	--	--	--	--	--	--	--	--	--	--
637839	--	--	--	--	--	--	1	--	--	--	--

INDIVIDUAL RED BLOOD CELL MORPHOLOGY VALUES FOR MALE RATS

Animal Number	NORM	ANIS	MICR	MACR	POLY	HYPO	ECHI	ACAN	TARG	RX	HJB
Male, Group: I - 0 mg/m ³ - Day 25											
637805	--	--	--	--	--	--	2	1	--	--	--
637806	--	--	--	--	--	--	2	1	--	--	--
637807	--	--	--	--	--	--	1	--	--	--	--
637808	--	2	1	1	--	--	2	1	--	--	--
637809	--	1	1	--	--	--	3	1	--	--	--
Male, Group: III - 25 mg/m ³ - Day 25											
637815	--	--	--	--	--	--	2	--	--	--	--
637816	--	--	--	--	--	--	1	1	--	--	--
637817	--	--	--	--	1	--	2	1	--	--	--
637818	--	--	--	--	--	--	1	1	--	--	--
637819	--	--	--	--	--	--	3	1	--	--	--
Male, Group: V - 125 mg/m ³ - Day 25											
637825	--	--	--	--	--	--	2	1	--	--	--
637826	--	--	--	--	--	--	2	2	--	--	--
637827	--	--	--	--	--	--	4	2	--	--	--
637828	--	--	--	--	--	--	2	1	--	--	--
637829	--	--	--	--	1	--	2	1	--	--	--
Male, Group: VII - 600 mg/m ³ - Day 25											
637835	--	--	--	--	--	--	2	1	--	--	--
637836	--	--	--	--	--	--	2	1	--	--	--
637837	--	--	--	--	--	--	2	1	--	--	--
637838	--	--	--	--	--	--	1	--	--	--	--
637839	--	--	--	--	--	--	2	1	--	--	--

INDIVIDUAL WHITE BLOOD CELL / PLATELET MORPHOLOGY VALUES FOR MALE RATS

Animal Number	NORM	SM	TG	DB	VN	PC	GP	BP	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 11									
637800	--	--	--	--	--	1	--	--	DECR PLATELET
637801	NORMAL	--	--	--	--	--	--	--	--
637802	--	--	--	--	--	1	--	--	DECR PLATELET
637803	NORMAL	--	--	--	--	--	--	--	--
637804	--	--	--	--	--	1	--	--	DECR PLATELET
637805	NORMAL	--	--	--	--	--	--	--	--
637806	NORMAL	--	--	--	--	--	--	--	--
637807	NORMAL	--	--	--	--	--	--	--	--
637808	NORMAL	--	--	--	--	--	--	--	--
637809	NORMAL	--	--	--	--	--	--	--	--
Male, Group: III - 25 mg/m ³ - Day 11									
637810	NORMAL	--	--	--	--	--	--	--	--
637811	NORMAL	--	--	--	--	--	--	--	--
637812	NORMAL	--	--	--	--	--	--	--	--
637813	NORMAL	--	--	--	--	--	--	--	--
637814	NORMAL	--	--	--	--	--	--	--	--
637815	--	--	--	--	--	--	--	--	--
637816	NORMAL	--	--	--	--	1	--	--	DECR PLATELET
637817	NORMAL	--	--	--	--	--	--	--	--
637818	NORMAL	--	--	--	--	--	--	--	--
637819	NORMAL	--	--	--	--	--	--	--	--

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

INDIVIDUAL WHITE BLOOD CELL / PLATELET MORPHOLOGY VALUES FOR MALE RATS

Animal Number	NORM	SM	TG	DB	VN	PC	GP	BP	SPECIAL OBSERVATIONS
Male, Group: V - 125 mg/m ³ - Day 11									
637820	NORMAL	--	--	--	--	--	--	--	
637821	NORMAL	--	--	--	--	--	--	--	
637822	NORMAL	--	--	--	--	--	--	--	
637823	NORMAL	--	--	--	--	--	--	--	
637824	NORMAL	--	--	--	--	--	--	--	
637825	NORMAL	--	--	--	--	--	--	--	
637826	NORMAL	--	--	--	--	--	--	--	
637827	NORMAL	--	--	--	--	1	--	--	UTD
637828	--	--	--	--	--	--	--	--	
637829	NORMAL	--	--	--	--	--	--	--	
Male, Group: VII - 600 mg/m ³ - Day 11									
637830	--	--	--	--	--	1	--	--	DECR PLATELET
637831	NORMAL	--	--	--	--	--	--	--	
637832	NORMAL	--	--	--	--	--	--	--	
637833	NORMAL	--	--	--	--	--	--	--	
637834	NORMAL	--	--	--	--	--	--	--	
637835	NORMAL	--	--	--	--	--	--	--	
637836	NORMAL	--	--	--	--	--	--	--	
637837	NORMAL	--	--	--	--	--	--	--	
637838	NORMAL	--	--	--	--	--	--	--	
637839	NORMAL	--	--	--	--	--	--	--	

INDIVIDUAL WHITE BLOOD CELL / PLATELET MORPHOLOGY VALUES FOR MALE RATS

Animal Number	NORM	SM	TG	DB	VN	PC	GP	BP	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 25									
637805	NORMAL	--	--	--	--	--	--	--	
637806	--	--	--	--	--	1	--	--	DECR PLATELET
637807	NORMAL	--	--	--	--	--	--	--	
637808	NORMAL	--	--	--	--	--	--	--	
637809	NORMAL	--	--	--	--	--	--	--	
Male, Group: III - 25 mg/m ³ - Day 25									
637815	--	--	--	--	--	1	--	--	DECR PLATELET
637816	NORMAL	--	--	--	--	--	--	--	
637817	NORMAL	--	--	--	--	--	--	--	
637818	NORMAL	--	--	--	--	--	--	--	
637819	--	--	--	--	--	1	--	--	ADEQ PLATELET
Male, Group: V - 125 mg/m ³ - Day 25									
637825	NORMAL	--	--	--	--	--	--	--	
637826	NORMAL	--	--	--	--	--	--	--	
637827	NORMAL	--	--	--	--	--	--	--	
637828	NORMAL	--	--	--	--	--	--	--	
637829	NORMAL	--	--	--	--	--	--	--	
Male, Group: VII - 600 mg/m ³ - Day 25									
637835	NORMAL	--	--	--	--	--	--	--	
637836	NORMAL	--	--	--	--	--	--	--	
637837	NORMAL	--	--	--	--	--	--	--	
637838	NORMAL	--	--	--	--	--	--	--	
637839	NORMAL	--	--	--	--	--	--	--	

INDIVIDUAL COAGULATION VALUES FOR MALE RATS

Animal Number	PHEM	PLIP	PICT	PT sec	APTT sec
Male, Group: I - 0 mg/m ³ - Day 11					
637800	NONE	NONE	NONE	14.3	20.0
637801	NONE	NONE	NONE	15.3	14.5
637802	TRACE	NONE	NONE	18.0	28.8
637803	TRACE	NONE	NONE	16.5	22.1
637804	NONE	NONE	NONE	14.7	13.9
Male, Group: III - 25 mg/m ³ - Day 11					
637810	NONE	NONE	NONE	15.5	25.9
637811	NONE	NONE	NONE	14.9	22.5
637812	NONE	NONE	NONE	15.0	21.5
637813	NONE	NONE	NONE	15.5	17.1
637814	NONE	NONE	NONE	15.0	18.0
Male, Group: V - 125 mg/m ³ - Day 11					
637820	MODERATE	NONE	NONE	15.2	17.8
637821	NONE	NONE	NONE	14.6	17.2
637822	NONE	NONE	NONE	16.9	19.0
637823	NONE	NONE	NONE	15.1	14.8
637824	NONE	NONE	NONE		
Male, Group: VII - 600 mg/m ³ - Day 11					
637830	NONE	NONE	NONE	15.2	25.8
637831	NONE	NONE	NONE	14.8	17.7
637832	TRACE	NONE	NONE	15.0	19.5
637833	NONE	NONE	NONE	15.8	20.8
637834	NONE	NONE	NONE	14.7	16.5

INDIVIDUAL COAGULATION VALUES FOR MALE RATS

Animal Number	PHEM	PLIP	PICT	PT sec	APTT sec
Male, Group: I - 0 mg/m ³ - Day 25					
637805	NONE	NONE	NONE	14.2	18.0
637806	NONE	NONE	NONE	15.2	19.0
637807	TRACE	NONE	NONE	15.7	23.5
637808	NONE	NONE	NONE	14.3	18.6
637809	NONE	NONE	NONE	14.8	15.9
Male, Group: III - 25 mg/m ³ - Day 25					
637815	NONE	NONE	NONE	14.9	18.0
637816	TRACE	NONE	NONE	15.8	23.0
637817	NONE	NONE	NONE	16.4	23.3
637818	NONE	NONE	NONE	15.5	17.3
637819	NONE	NONE	NONE	14.2	13.8
Male, Group: V - 125 mg/m ³ - Day 25					
637825	NONE	NONE	NONE	14.6	17.3
637826	NONE	NONE	NONE	14.1	15.4
637827	TRACE	NONE	NONE	14.3	15.9
637828	TRACE	NONE	NONE	14.7	16.1
637829	NONE	NONE	NONE	14.8	19.0
Male, Group: VII - 600 mg/m ³ - Day 25					
637835	TRACE	NONE	NONE	14.1	14.9
637836	NONE	NONE	NONE	14.5	17.7
637837	NONE	NONE	NONE	16.2	21.0
637838	NONE	NONE	NONE	13.9	15.7
637839	NONE	NONE	NONE	14.6	16.1

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	SEMI	SLIP	SICT	AST IU/L	ALT IU/L	SDH IU/L	ALKP IU/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group: I - 0 mg/m ³ - Day 11											
637800	NONE	NONE	NONE	88	35	18.1	241	<0.10	15	0.31	76
637801	NONE	NONE	NONE	86	32	20.5	236	0.11	12	0.33	110
637802	NONE	NONE	NONE	90	39	20.7	172	<0.10	17	0.42	40
637803	NONE	NONE	NONE	81	27	16.2	209	<0.10	10	0.30	56
637804	NONE	NONE	NONE	135	44	23.4	186	<0.10	14	0.37	53
637805	NONE	NONE	NONE	85	34	14.1	165	0.13	15	0.39	63
637806	NONE	NONE	NONE	105	48	17.6	275	0.10	11	0.28	59
637807	NONE	NONE	NONE	84	35	14.0	239	0.10	12	0.28	45
637808	NONE	NONE	NONE	100	41	16.2	263	<0.10	13	0.27	74
637809	NONE	NONE	NONE	100	42	15.2	208	0.12	12	0.34	70
Male, Group: III - 25 mg/m ³ - Day 11											
637810	NONE	NONE	NONE	122	40	12.7	155	<0.10	14	0.40	81
637811	NONE	NONE	NONE	86	44	15.7	174	<0.10	15	0.44	58
637812	NONE	NONE	NONE	76	44	14.8	256	<0.10	17	0.32	70
637813	NONE	NONE	NONE	83	36	14.0	200	0.14	16	0.41	52
637814	NONE	NONE	NONE	100	51	19.9	196	0.10	18	0.38	54
637815	NONE	NONE	NONE	87	40	17.4	176	0.10	17	0.39	67
637816	NONE	NONE	NONE	131	51	20.7	190	0.11	16	0.39	69
637817	NONE	NONE	NONE	113	40	15.0	187	<0.10	17	0.50	48
637818	NONE	NONE	NONE	83	37	14.3	211	0.14	21	0.41	69
637819	NONE	NONE	NONE	98	43	18.3	183	<0.10	14	0.34	84

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	SHEM	SLIP	SICT	AST IU/L	ALT IU/L	SDH IU/L	ALKP IU/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group: V - 125 mg/m ³ - Day 11											
637820	NONE	NONE	NONE	66	29	16.6	125	<0.10	11	0.37	93
637821	NONE	NONE	NONE	79	39	15.9	273	0.11	16	0.34	69
637822	NONE	NONE	NONE	81	37	18.2	186	<0.10	16	0.47	89
637823	NONE	NONE	NONE	105	42	21.1	218	<0.10	16	0.40	69
637824	NONE	NONE	NONE	74	40	11.0	193	0.12	17	0.34	80
637825	NONE	NONE	NONE	79	27	14.6	232	<0.10	14	0.34	80
637826	NONE	NONE	NONE	78	39	15.3	273	<0.10	17	0.41	108
637827	NONE	NONE	NONE	87	34	14.2	130	<0.10	12	0.31	113
637828	NONE	NONE	NONE	104	31	14.6	185	<0.10	15	0.40	78
637829	NONE	NONE	NONE	81	36	13.3	174	0.11	12	0.40	53
Male, Group: VII - 600 mg/m ³ - Day 11											
637830	NONE	NONE	NONE	81	36	17.6	171	<0.10	37	0.71	72
637831	NONE	NONE	NONE	108	38	11.4	184	0.11	20	0.39	68
637832	NONE	NONE	NONE	75	43	14.2	184	<0.10	16	0.41	91
637833	NONE	NONE	NONE	74	36	11.7	178	0.14	22	0.39	76
637834	NONE	NONE	NONE	93	72	17.0	207	0.19	19	0.36	88
637835	NONE	NONE	NONE	75	44	15.0	127	0.10	19	0.43	79
637836	NONE	NONE	NONE	114	37	21.4	199	<0.10	15	0.45	94
637837	NONE	NONE	NONE	78	38	14.3	243	0.10	21	0.51	71
637838	NONE	NONE	NONE	98	51	16.6	176	<0.10	16	0.39	89
637839	NONE	NONE	NONE	98	52	22.3	141	0.11	21	0.45	117

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L
Male, Group: I - 0 mg/m ³ - Day 11										
637800	73	94	5.7	4.0	1.7	10.8	10.3	147.6	6.33	94.2
637801	46	93	5.8	4.2	1.6	10.6	9.4	149.0	5.68	95.0
637802	36	78	6.0	4.0	2.0	10.7	10.0	148.9	6.12	93.9
637803	38	84	6.4	4.1	1.9	10.5	8.6	150.3	6.17	96.3
637804	44	104	6.3	4.3	2.1	11.9	12.0	150.0	6.91	96.9
637805	38	87	6.3	4.2	2.1	11.0	10.3	148.2	6.30	94.8
637806	50	94	6.2	4.3	1.9	10.8	8.9	149.9	5.96	96.2
637807	22	91	5.9	4.1	1.8	10.8	9.7	151.0	6.07	95.1
637808	44	82	5.9	4.0	1.9	11.0	10.0	149.7	6.46	95.2
637809	63	90	6.3	4.3	2.0	10.7	10.7	146.5	6.09	96.3
Male, Group: III - 25 mg/m ³ - Day 11										
637810	56	69	6.3	4.3	2.0	10.8	10.3	146.3	6.46	99.4
637811	26	88	5.8	4.2	1.6	10.6	10.0	148.8	5.74	98.1
637812	49	87	6.1	4.3	1.8	11.3	9.7	150.5	5.95	95.0
637813	19	91	6.1	4.2	1.9	11.0	9.5	149.7	6.04	98.3
637814	24	90	6.3	4.1	2.2	10.5	9.4	148.0	5.72	97.5
637815	29	85	6.8	4.7	2.1	11.2	9.0	149.5	6.50	98.2
637816	34	86	5.8	4.2	1.6	10.8	10.1	148.1	6.50	97.5
637817	24	85	6.6	4.5	2.1	10.7	9.5	148.6	6.30	99.7
637818	22	87	6.7	4.6	2.1	11.2	9.8	150.0	6.19	97.1
637819	41	83	6.2	4.4	1.8	11.1	9.3	150.8	6.37	97.6

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L
Male, Group: V - 125 mg/m ³ - Day 11										
637820	40	81	6.3	4.5	1.8	10.9	9.4	149.0	6.18	94.8
637821	34	82	6.3	4.3	2.0	11.0	9.6	149.2	6.09	95.2
637822	31	93	6.4	4.6	1.8	11.1	9.6	148.3	5.82	96.2
637823	47	81	6.0	4.3	1.7	11.0	10.0	148.7	6.18	97.1
637824	35	77	6.4	4.4	2.0	11.5	9.1	149.4	5.94	96.7
637825	23	97	6.1	4.4	1.7	10.7	9.8	147.9	6.43	97.9
637826	54	109	5.9	4.3	1.6	11.0	10.3	146.5	5.72	94.9
637827	34	90	5.9	4.3	1.6	10.8	9.3	147.9	5.67	96.9
637828	49	85	6.0	4.2	1.8	11.1	10.3	149.9	6.23	101.0
637829	51	92	6.2	4.4	1.8	11.1	9.7	149.1	6.12	93.6
Male, Group: VII - 600 mg/m ³ - Day 11										
637830	54	83	6.7	4.7	2.0	11.0	11.2	143.1	6.21	89.6
637831	38	81	6.2	4.4	1.8	11.1	9.2	145.2	5.50	93.6
637832	53	93	6.2	4.2	2.0	11.2	9.1	149.0	6.04	96.1
637833	30	92	6.4	4.5	1.9	11.2	8.6	146.4	5.35	91.0
637834	38	89	6.6	4.7	1.9	11.8	9.8	147.8	6.11	92.0
637835	27	95	6.8	4.8	2.0	11.4	9.4	146.3	5.70	92.0
637836	35	94	5.9	4.3	1.6	10.9	10.0	149.3	5.93	97.2
637837	32	91	7.0	4.8	2.2	11.5	9.9	150.7	6.11	93.5
637838	36	88	6.7	4.5	2.2	11.3	9.3	148.0	6.02	96.2
637839	40	88	6.8	4.3	2.5	11.2	9.5	146.6	6.28	93.2

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	PFLU	FHEM	FLIP	FICT
Male, Group: I - 0 mg/m ³ - Day 11				
637800	0.1	NONE	NONE	NONE
637801	0.1	NONE	NONE	NONE
637802	0.1	TRACE	NONE	NONE
637803	0.1	NONE	NONE	NONE
637804	0.1	NONE	NONE	NONE
Male, Group: III - 25 mg/m ³ - Day 11				
637810	0.1	NONE	NONE	NONE
637811	0.1	NONE	NONE	NONE
637812	0.1	NONE	NONE	NONE
637813	0.1	NONE	NONE	NONE
637814	0.1	NONE	NONE	NONE
Male, Group: V - 125 mg/m ³ - Day 11				
637820	0.1	TRACE	NONE	NONE
637821	0.1	NONE	NONE	NONE
637822	0.1	NONE	NONE	NONE
637823	0.1	NONE	NONE	NONE
637824	0.1	NONE	NONE	NONE
Male, Group: VII - 600 mg/m ³ - Day 11				
637830	0.1	NONE	NONE	NONE
637831	0.1	NONE	NONE	NONE
637832	0.1	NONE	NONE	NONE
637833	0.1	NONE	NONE	NONE
637834	0.1	NONE	NONE	NONE

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	SHEM	SLIP	SICT	AST IU/L	ALT IU/L	SDH IU/L	ALKP IU/L	BILI mg/dL	BUN mg/dL	CREA mg/dL	CHOL mg/dL
Male, Group: I - 0 mg/m ³ - Day 25											
637805	NONE	NONE	NONE	87	44	24.3	148	0.12	18	0.51	73
637806	NONE	NONE	NONE	107	44	21.7	239	0.15	13	0.38	61
637807	NONE	NONE	NONE	77	40	18.0	210	0.12	12	0.41	50
637808	NONE	NONE	NONE	94	48	21.5	230	<0.10	14	0.42	73
637809	NONE	NONE	NONE	109	51	21.9	173	0.11	13	0.39	82
Male, Group: III - 25 mg/m ³ - Day 25											
637815	NONE	NONE	NONE	102	37	24.2	155	0.12	16	0.45	65
637816	TRACE	NONE	NONE	94	46	22.5	189	<0.10	15	0.44	73
637817	NONE	NONE	NONE	126	47	15.4	188	0.13	17	0.53	58
637818	NONE	NONE	NONE	98	43	24.8	195	0.16	15	0.55	80
637819	NONE	NONE	NONE	100	47	25.7	199	0.17	16	0.41	100
Male, Group: V - 125 mg/m ³ - Day 25											
637825	TRACE	NONE	NONE	119	38	24.8	215	0.12	13	0.44	64
637826	NONE	NONE	NONE	90	39	19.7	238	0.13	14	0.41	86
637827	NONE	NONE	NONE	87	44	16.7	138	0.10	14	0.45	102
637828	NONE	NONE	NONE	88	42	20.9	186	0.12	15	0.43	74
637829	NONE	NONE	NONE	77	37	18.9	181	<0.10	13	0.38	56
Male, Group: VII - 600 mg/m ³ - Day 25											
637835	NONE	NONE	NONE	110	51	24.4	126	0.14	15	0.45	65
637836	TRACE	NONE	NONE	125	35	10.0	184	0.14	19	0.38	94
637837	NONE	NONE	NONE	83	45	19.2	212	0.11	17	0.35	64
637838	NONE	NONE	NONE	85	46	19.7	186	0.15	15	0.37	73
637839	NONE	NONE	NONE	82	38	25.2	138	0.10	16	0.32	85

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	TRIG mg/dL	GLUC mg/dL	TP g/dL	ALB g/dL	GLOB g/dL	CALC mg/dL	IPHS mg/dL	NA mmol/L	K mmol/L	CL mmol/L
Male, Group: I - 0 mg/m ³ - Day 25										
637805	49	83	7.5	4.8	2.7	11.3	9.0	151.5	5.99	93.0
637806	61	100	6.9	4.7	2.2	10.9	8.6	149.3	5.61	96.7
637807	22	95	6.8	4.8	2.0	10.8	8.7	151.9	5.73	95.8
637808	71	109	6.3	4.3	2.0	10.7	9.7	150.1	6.66	97.1
637809	99	86	6.9	4.6	2.3	10.8	7.9	149.8	5.92	97.1
Male, Group: III - 25 mg/m ³ - Day 25										
637815	55	76	7.0	4.7	2.3	10.7	8.2	151.8	6.15	99.1
637816	83	97	6.9	4.8	2.1	10.8	9.4	150.1	6.30	95.0
637817	53	82	7.2	4.8	2.4	10.7	7.8	149.7	6.25	98.4
637818	42	91	7.2	5.0	2.2	11.2	9.3	151.0	6.30	94.7
637819	73	99	6.8	4.7	2.1	10.9	8.9	150.1	6.34	98.0
Male, Group: V - 125 mg/m ³ - Day 25										
637825	32	80	6.8	4.9	1.9	10.6	8.0	150.0	5.88	95.1
637826	76	110	6.3	4.5	1.8	10.4	8.9	149.1	5.64	96.8
637827	78	98	6.6	4.7	1.9	10.9	8.5	152.6	5.61	97.4
637828	78	93	6.5	4.6	1.9	10.9	8.5	151.0	6.26	97.6
637829	95	94	6.7	4.8	1.9	11.2	9.2	151.6	6.41	97.0
Male, Group: VII - 600 mg/m ³ - Day 25										
637835	45	95	7.1	4.9	2.2	10.7	8.4	149.3	5.73	96.2
637836	54	104	6.5	4.7	1.8	10.6	9.1	148.0	6.03	98.5
637837	37	90	6.8	4.6	2.2	11.2	9.1	151.2	6.11	96.4
637838	38	93	6.8	4.7	2.1	11.1	10.0	151.3	5.88	95.8
637839	43	78	6.6	4.4	2.2	11.0	9.3	150.7	6.23	97.9

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

INDIVIDUAL SERUM CHEMISTRY VALUES FOR MALE RATS

Animal Number	PFLU	PHEM	FLIP	PICT
Male, Group: I - 0 mg/m ³ - Day 25				
637805	0.1	TRACE	NONE	NONE
637806	0.1	NONE	NONE	NONE
637807	0.1	NONE	NONE	NONE
637808	0.1	NONE	NONE	NONE
637809	0.1	NONE	TRACE	NONE
Male, Group: III - 25 mg/m ³ - Day 25				
637815	0.1	NONE	NONE	NONE
637816	0.1	NONE	NONE	NONE
637817	0.1	NONE	NONE	NONE
637818	0.1	NONE	NONE	NONE
637819	0.1	NONE	NONE	NONE
Male, Group: V - 125 mg/m ³ - Day 25				
637825	0.1	NONE	NONE	NONE
637826	0.1	TRACE	NONE	NONE
637827	0.1	NONE	NONE	NONE
637828	0.1	NONE	NONE	NONE
637829	0.1	NONE	NONE	NONE
Male, Group: VII - 600 mg/m ³ - Day 25				
637835	0.1	TRACE	NONE	NONE
637836	0.1	TRACE	NONE	NONE
637837	0.1	NONE	NONE	NONE
637838	0.1	NONE	NONE	NONE
637839	0.1	NONE	NONE	NONE

INDIVIDUAL URINALYSIS VALUES FOR MALE RATS

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mosm/kg	SG	pH	UPRO mg/dL	UGLU mg/dL	KET mg/dL	UBIL
Male, Group: I - 0 mg/m ³ - Day 11											
637800	DARK	BROWN	CLOUDY	6.3	1475	1.046	7.5	30	NEGATIVE	15	SMALL
637801	LIGHT	YELLOW	HAZY	9.4	808	1.025	6.5	TRACE	NEGATIVE	5	NEGATIVE
637802	LIGHT	YELLOW	HAZY	5.2	999	1.030	6.0	30	NEGATIVE	15	NEGATIVE
637803	LIGHT	YELLOW	CLEAR	5.5	1233	1.039	6.5	30	NEGATIVE	5	NEGATIVE
637804	LIGHT	YELLOW	CLEAR	26.0	330	1.012	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637805	LIGHT	YELLOW	CLEAR	3.2	1149	1.037	6.0	30	NEGATIVE	5	NEGATIVE
637806	LIGHT	YELLOW	CLEAR	12.2	688	1.022	5.5	TRACE	NEGATIVE	5	NEGATIVE
637807	LIGHT	YELLOW	CLEAR	9.1	696	1.021	6.5	TRACE	NEGATIVE	5	NEGATIVE
637808	LIGHT	YELLOW	HAZY	9.2	851	1.025	7.0	30	NEGATIVE	5	NEGATIVE
637809	NSR	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
Male, Group: III - 25 mg/m ³ - Day 11											
637810	LIGHT	YELLOW	CLEAR	6.0	1003	1.031	6.0	30	NEGATIVE	5	NEGATIVE
637811	LIGHT	YELLOW	CLEAR	8.2	852	1.026	7.0	TRACE	NEGATIVE	5	NEGATIVE
637812	LIGHT	YELLOW	CLEAR	11.0	685	1.023	6.0	TRACE	NEGATIVE	5	NEGATIVE
637813	LIGHT	YELLOW	HAZY	8.3	849	1.026	6.5	TRACE	NEGATIVE	NEGATIVE	NEGATIVE
637814	LIGHT	YELLOW	CLEAR	9.8	826	1.025	6.5	TRACE	NEGATIVE	5	NEGATIVE
637815	LIGHT	YELLOW	CLEAR	12.8	555	1.019	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637816	LIGHT	YELLOW	CLEAR	3.9	1006	1.031	5.5	30	NEGATIVE	NEGATIVE	NEGATIVE
637817	MEDIUM	YELLOW	CLEAR	4.0	1278	1.040	6.0	30	NEGATIVE	5	NEGATIVE
637818	LIGHT	YELLOW	CLEAR	12.0	672	1.022	6.5	TRACE	NEGATIVE	NEGATIVE	NEGATIVE
637819	LIGHT	YELLOW	CLEAR	13.6	578	1.019	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE

INDIVIDUAL URINALYSIS VALUES FOR MALE RATS

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	SG	pH	UPRO mg/dL	UGLU mg/dL	KET mg/dL	UBIL
Male, Group: V - 125 mg/m ³ - Day 11											
637820	MEDIUM	YELLOW	CLEAR	1.7	1023	1.036	5.0	TRACE	NEGATIVE	5	NEGATIVE
637821	LIGHT	YELLOW	CLEAR	15.8	365	1.012	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637822	LIGHT	YELLOW	CLEAR	13.4	499	1.018	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637823	MEDIUM	YELLOW	CLEAR	4.5	1416	1.047	5.5	30	NEGATIVE	NEGATIVE	NEGATIVE
637824	LIGHT	YELLOW	HAZY	9.7	779	1.025	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637825	LIGHT	YELLOW	HAZY	13.0	617	1.021	6.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637826	MEDIUM	YELLOW	CLEAR	6.7	1179	1.038	6.0	30	NEGATIVE	5	NEGATIVE
637827	LIGHT	YELLOW	CLEAR	8.0	522	1.018	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637828	MEDIUM	YELLOW	CLEAR	3.0	1717	1.055	5.5	30	NEGATIVE	5	NEGATIVE
637829	LIGHT	YELLOW	CLEAR	17.2	427	1.015	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
Male, Group: VII - 600 mg/m ³ - Day 11											
637830	LIGHT	YELLOW	HAZY	9.3	699	1.022	6.0	TRACE	NEGATIVE	NEGATIVE	NEGATIVE
637831	LIGHT	YELLOW	CLEAR	11.8	621	1.021	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637832	LIGHT	YELLOW	CLEAR	7.9	766	1.025	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637833	LIGHT	YELLOW	CLEAR	12.6	500	1.018	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637834	LIGHT	YELLOW	HAZY	7.3	1227	1.039	5.5	TRACE	NEGATIVE	5	NEGATIVE
637835	MEDIUM	YELLOW	HAZY	5.3	1166	1.038	5.5	TRACE	NEGATIVE	NEGATIVE	NEGATIVE
637836	LIGHT	YELLOW	CLEAR	10.0	791	1.025	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637837	LIGHT	YELLOW	CLEAR	10.0	602	1.019	5.5	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637838	LIGHT	YELLOW	HAZY	18.0	460	1.017	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637839	LIGHT	YELLOW	CLEAR	14.0	486	1.017	5.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE

INDIVIDUAL URINALYSIS VALUES FOR MALE RATS

Animal Number	BLD	URO EU/dL	UFLU µg	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 11				
637800	MODERATE	1.0	6.6	FECAL CONTAMINATION OBSERVED
637801	NEGATIVE	0.2	9.2	FECAL CONTAMINATION OBSERVED
637802	NEGATIVE	0.2	6.7	
637803	NEGATIVE	0.2	8.6	
637804	NEGATIVE	0.2	13.2	
637805	NEGATIVE	0.2	4.9	
637806	NEGATIVE	0.2	15.1	
637807	NEGATIVE	0.2	10.4	
637808	NEGATIVE	0.2	10.2	
637809	NT	NT	NSR	
Male, Group: III - 25 mg/m ³ - Day 11				
637810	NEGATIVE	0.2	7.3	
637811	NEGATIVE	0.2	10.1	
637812	NEGATIVE	0.2	10.9	
637813	TRACE	0.2	13.0	FECAL CONTAMINATION OBSERVED
637814	NEGATIVE	0.2	14.8	
637815	NEGATIVE	0.2	11.7	
637816	NEGATIVE	0.2	5.7	
637817	NEGATIVE	0.2	7.4	
637818	NEGATIVE	0.2	12.6	
637819	NEGATIVE	0.2	14.2	

INDIVIDUAL URINALYSIS VALUES FOR MALE RATS

Animal Number	BLD	URO EU/dL	UFLU µg	SPECIAL OBSERVATIONS
Male, Group: V - 125 mg/m ³ - Day 11				
637820	NEGATIVE	0.2	4.1	
637821	NEGATIVE	0.2	15.7	
637822	NEGATIVE	0.2	17.6	
637823	NEGATIVE	0.2	13.3	
637824	NEGATIVE	0.2	18.4	
637825	NEGATIVE	0.2	21.8	
637826	NEGATIVE	0.2	17.8	
637827	NEGATIVE	0.2	12.5	
637828	NEGATIVE	0.2	11.6	
637829	NEGATIVE	0.2	15.3	
Male, Group: VII - 500 mg/m ³ - Day 11				
637830	NEGATIVE	0.2	8.1	
637831	NEGATIVE	0.2	13.9	
637832	NEGATIVE	0.2	11.2	
637833	NEGATIVE	0.2	10.9	
637834	NEGATIVE	0.2	12.9	
637835	NEGATIVE	0.2	11.7	
637836	NEGATIVE	0.2	14.7	
637837	TRACE	0.2	13.2	
637838	NEGATIVE	0.2	18.9	
637839	NEGATIVE	0.2	13.6	

INDIVIDUAL URINALYSIS VALUES FOR MALE RATS

Animal Number	QUAL	COL	CLAR	VOL mL	UOSM mOsm/kg	SG	pH	UPRO mg/dL	UGLU mg/dL	KET mg/dL	UBIL
Male, Group: I - 0 mg/m ³ - Day 25											
637805	MEDIUM	YELLOW	HAZY	6.4	1274	1.041	6.5	30	NEGATIVE	15	NEGATIVE
637806	MEDIUM	YELLOW	CLEAR	4.3	1394	1.044	6.5	30	NEGATIVE	15	NEGATIVE
637807	LIGHT	YELLOW	CLEAR	15.4	551	1.018	6.5	TRACE	NEGATIVE	5	NEGATIVE
637808	LIGHT	YELLOW	CLOUDY	13.4	729	1.023	7.0	TRACE	NEGATIVE	5	NEGATIVE
637809	LIGHT	YELLOW	CLEAR	23.2	390	1.014	6.0	TRACE	NEGATIVE	5	NEGATIVE
Male, Group: III - 25 mg/m ³ - Day 25											
637815	LIGHT	YELLOW	CLEAR	14.2	483	1.015	6.0	NEGATIVE	NEGATIVE	5	NEGATIVE
637816	LIGHT	YELLOW	CLEAR	9.7	882	1.026	6.5	30	NEGATIVE	5	NEGATIVE
637817	MEDIUM	YELLOW	CLEAR	5.4	1030	1.031	6.5	30	NEGATIVE	5	NEGATIVE
637818	LIGHT	YELLOW	CLOUDY	20.8	462	1.015	6.5	TRACE	NEGATIVE	NEGATIVE	NEGATIVE
637819	LIGHT	YELLOW	HAZY	13.2	670	1.022	6.0	TRACE	NEGATIVE	NEGATIVE	NEGATIVE
Male, Group: V - 125 mg/m ³ - Day 25											
637825	LIGHT	YELLOW	HAZY	20.6	470	1.015	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637826	LIGHT	YELLOW	CLEAR	9.2	1016	1.030	7.0	30	NEGATIVE	5	NEGATIVE
637827	LIGHT	YELLOW	CLOUDY	10.8	567	1.020	6.0	TRACE	NEGATIVE	NEGATIVE	NEGATIVE
637828	LIGHT	YELLOW	CLOUDY	13.4	648	1.022	6.0	TRACE	NEGATIVE	5	NEGATIVE
637829	LIGHT	YELLOW	CLEAR	15.2	605	1.020	5.5	NEGATIVE	NEGATIVE	5	NEGATIVE
Male, Group: VII - 600 mg/m ³ - Day 25											
637835	LIGHT	YELLOW	CLEAR	24.0	355	1.012	6.0	NEGATIVE	NEGATIVE	NEGATIVE	NEGATIVE
637836	MEDIUM	YELLOW	HAZY	6.7	1386	1.044	6.0	30	NEGATIVE	5	NEGATIVE
637837	MEDIUM	YELLOW	CLEAR	2.5	1329	1.042	5.5	30	NEGATIVE	5	NEGATIVE
637838	LIGHT	YELLOW	CLEAR	12.4	760	1.024	6.0	TRACE	NEGATIVE	5	NEGATIVE
637839	MEDIUM	YELLOW	CLEAR	7.3	956	1.029	6.5	TRACE	NEGATIVE	5	NEGATIVE

INDIVIDUAL URINALYSIS VALUES FOR MALE RATS

Animal Number	BLD	URO EU/dL	UFLU µg	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 25				
637805	NEGATIVE	0.2	7.7	
637806	NEGATIVE	0.2	7.1	
637807	NEGATIVE	0.2	12.1	
637808	NEGATIVE	0.2	14.5	
637809	NEGATIVE	0.2	16.3	
Male, Group: III - 25 mg/m ³ - Day 25				
637815	NEGATIVE	0.2	12.2	
637816	TRACE	0.2	10.9	
637817	NEGATIVE	0.2	8.5	
637818	TRACE	0.2	15.4	FECAL CONTAMINATION OBSERVED
637819	NEGATIVE	0.2	13.5	
Male, Group: V - 125 mg/m ³ - Day 25				
637825	NEGATIVE	0.2	16.2	
637826	NEGATIVE	0.2	15.1	
637827	SMALL	0.2	11.0	FECAL CONTAMINATION OBSERVED
637828	TRACE	0.2	18.3	FECAL CONTAMINATION OBSERVED
637829	NEGATIVE	0.2	16.1	
Male, Group: VII - 600 mg/m ³ - Day 25				
637835	NEGATIVE	0.2	16.8	
637836	NEGATIVE	0.2	13.4	
637837	NEGATIVE	0.2	5.3	
637838	NEGATIVE	0.2	15.0	
637839	NEGATIVE	0.2	12.0	

INDIVIDUAL URINE MICROSCOPIC VALUES FOR MALE RATS

Animal Number	EPIT	WBC	URBC	NCRY	MICR	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 11						
637800	NT	NT	NT	NT	NT	GROSSLY CONTAMINATED WITH FECAL MATERIAL, UNABLE TO DETERMINE; CELLULAR MATERIAL.
637801	FEW	0	0	NONE	FEW	1-SPERM
637802	FEW	1-10	0	NONE	FEW	1-SPERM
637803	FEW	0	0	NONE	FEW	
637804	FEW	0	0	NONE	FEW	
637805	FEW	0	0	NONE	FEW	1-SPERM
637806	FEW	0	0	NONE	FEW	1-SPERM
637807	FEW	0	0	NONE	FEW	
637808	FEW	0	0	NONE	FEW	
637809	NSR	NT	NT	NT	NT	
Male, Group: III - 25 mg/m ³ - Day 11						
637810	FEW	0	0	NONE	FEW	1-SPERM
637811	FEW	0	0	NONE	FEW	1-SPERM
637812	NONE	0	0	NONE	FEW	1-SPERM
637813	FEW	0	0	NONE	MODERATE	
637814	NONE	0	0	NONE	FEW	
637815	NONE	1-10	0	NONE	FEW	1-SPERM
637816	NONE	1-10	0	NONE	FEW	
637817	NONE	0	0	NONE	FEW	
637818	FEW	0	0	NONE	NONE	1-SPERM
637819	FEW	0	0	NONE	NONE	

INDIVIDUAL URINE MICROSCOPIC VALUES FOR MALE RATS

Animal Number	EPIT	UWBC	URBC	NCRY	MICR	SPECIAL OBSERVATIONS
Male, Group: V - 125 mg/m ³ - Day 11						
637820	FEW	0	0	FEW	FEW	Sample status: BELOW RECOMMENDED VOLUME
637821	FEW	0	0	NONE	FEW	1-SPERM
637822	FEW	1-10	0	NONE	FEW	1-SPERM
637823	FEW	0	0	NONE	FEW	1-SPERM
637824	FEW	1-10	0	NONE	FEW	1-SPERM
637825	FEW	0	0	NONE	FEW	1-SPERM
637826	FEW	0	0	NONE	FEW	1-SPERM
637827	FEW	0	0	NONE	NONE	
637828	FEW	0	0	NONE	FEW	
637829	FEW	0	0	NONE	FEW	1-SPERM
Male, Group: VII - 600 mg/m ³ - Day 11						
637830	FEW	0	0	FEW	FEW	1-SPERM
637831	FEW	0	0	NONE	FEW	
637832	NONE	0	0	NONE	FEW	
637833	FEW	1-10	0	NONE	FEW	
637834	FEW	1-10	0	NONE	FEW	
637835	NONE	0	0	NONE	FEW	1-SPERM
637836	NONE	0	0	NONE	FEW	1-SPERM
637837	NONE	0	0	NONE	FEW	
637838	FEW	0	0	NONE	FEW	
637839	FEW	0	0	NONE	FEW	

INDIVIDUAL URINE MICROSCOPIC VALUES FOR MALE RATS

Animal Number	EPIT	WBC	URBC	NCRY	MICR	SPECIAL OBSERVATIONS
Male, Group: I - 0 mg/m ³ - Day 25						
637805	NONE	0	0	NONE	MODERATE	2-SPERM
637806	NONE	0	0	NONE	MODERATE	2-SPERM; 1-MUCUS
637807	NONE	0	0	NONE	FEW	1-SPERM; 1-MUCUS
637808	NONE	0	0	FEW	FEW	1-SPERM
637809	NONE	0	0	NONE	FEW	1-SPERM
Male, Group: III - 25 mg/m ³ - Day 25						
637815	NONE	0	0	NONE	FEW	2-SPERM; 1-MUCUS
637816	NONE	1-10	0	NONE	MODERATE	1-MUCUS
637817	NONE	0	0	NONE	MODERATE	1-MUCUS
637818	FEW	0	0	NONE	MANY	2-SPERM
637819	FEW	0	0	NONE	FEW	1-SPERM; 1-MUCUS
Male, Group: V - 125 mg/m ³ - Day 25						
637825	FEW	0	0	NONE	FEW	1-SPERM
637826	NONE	0	0	FEW	FEW	1-SPERM
637827	FEW	0	0	NONE	MODERATE	1-SPERM
637828	NONE	0	0	NONE	MANY	1-MUCUS
637829	NONE	0	0	NONE	FEW	1-MUCUS
Male, Group: VII - 600 mg/m ³ - Day 25						
637835	FEW	0	0	NONE	FEW	1-SPERM; 1-MUCUS
637836	FEW	0	0	NONE	MODERATE	2-SPERM; 1-MUCUS
637837	NONE	0	0	NONE	FEW	2-SPERM; 1-MUCUS
637838	NONE	0	0	NONE	FEW	1-MUCUS
637839	NONE	0	0	NONE	MODERATE	2-SPERM; 1-MUCUS

APPENDIX F

Individual Animal Final Body and Organ Weights

Individual Animal Final Body and Organ Weights

Group : I - 0 mg/m³ Treatment : 0 mg/m³ I Sex : MALES

ANIMAL	FINA (Gms)	BRAIN (Gms)	%FINA	KIDNEYS (Gms)	%FINA	%BRAIN	LIVER (Gms)	%FINA	%BRAIN	LUNGS (Gms)	%FINA	%BRAIN	TESTES (Gms)	%FINA	%BRAIN
637800	327.00	1.887	0.5771	2.932	0.8966	155.38	11.066	3.3841	586.43	1.760	0.5382	93.270	2.449	0.7489	129.78
637801	303.00	1.954	0.6449	2.734	0.9023	139.92	10.028	3.3096	513.20	1.727	0.5700	88.383	3.093	1.0208	158.29
637802	317.00	1.963	0.6192	2.566	0.8095	130.72	11.165	3.5221	568.77	2.013	0.6350	102.55	2.701	0.8521	137.60
637803	313.00	2.011	0.6425	3.328	1.0633	165.49	10.472	3.3457	520.74	1.803	0.5760	89.657	3.385	1.0815	168.32
637804	299.00	1.871	0.6258	2.601	0.8699	139.02	10.013	3.3488	535.17	1.708	0.5712	91.288	2.580	0.8629	137.89
Mean	311.80	1.937	0.6219	2.832	0.9083	146.10	10.549	3.3821	544.86	1.802	0.5781	93.029	2.842	0.9132	146.38
S.D.	11.19	0.058	0.0273	0.312	0.0941	14.027	0.550	0.0826	31.536	0.123	0.0352	5.6268	0.388	0.1352	16.187

Group : III - 25 mg/m³ Treatment : 25 mg/m³ III Sex : MALES

ANIMAL	FINA (Gms)	BRAIN (Gms)	%FINA	KIDNEYS (Gms)	%FINA	%BRAIN	LIVER (Gms)	%FINA	%BRAIN	LUNGS (Gms)	%FINA	%BRAIN	TESTES (Gms)	%FINA	%BRAIN
637810	293.00	1.964	0.6703	2.780	0.9488	141.55	10.326	3.5242	525.76	1.488	0.5078	75.764	3.226	1.1010	164.26
637811	298.00	1.868	0.6268	2.931	0.9836	156.91	9.305	3.1225	498.13	1.510	0.5067	80.835	3.677	1.2339	196.84
637812	303.00	1.918	0.6330	2.948	0.9729	153.70	9.844	3.2488	513.24	1.631	0.5383	85.036	3.282	1.0832	171.12
637813	291.00	1.840	0.6323	2.832	0.9732	153.91	9.138	3.1402	496.63	1.407	0.4835	76.467	3.321	1.1412	180.49
637814	287.00	1.742	0.6070	2.321	0.8087	133.24	8.929	3.1111	512.57	1.448	0.5045	83.123	3.187	1.1105	182.95
Mean	294.40	1.866	0.6339	2.762	0.9374	147.86	9.508	3.2294	509.27	1.497	0.5082	80.245	3.339	1.1340	179.13
S.D.	6.23	0.084	0.0229	0.256	0.0731	10.078	0.569	0.1737	12.069	0.085	0.0196	4.0602	0.196	0.0597	12.406

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

Individual Animal Final Body and Organ Weights

Group : V - 125 mg/m³ Treatment : 125 mg/m³ V Sex : MALES

ANIMAL	FINA (Gms)	BRAIN		KIDNEYS		LIVER		LUNGS		TESTES	
		(Gms)	%FINA	(Gms)	%FINA %BRAIN	(Gms)	%FINA %BRAIN	(Gms)	%FINA %BRAIN	(Gms)	%FINA %BRAIN
637820	288.00	1.932	0.6708	2.667	0.9260 138.04	10.901	3.7851 564.23	2.478	0.8604 128.26	3.334	1.1576 172.57
637821	284.00	1.902	0.7205	2.489	0.9428 130.86	8.605	3.2595 452.42	1.666	0.6311 87.592	3.398	1.2871 178.65
637822	282.00	1.834	0.6504	2.722	0.9652 148.42	9.355	3.3174 510.09	1.903	0.6748 103.76	3.202	1.1355 174.59
637823	290.00	2.077	0.7162	2.972	1.0248 143.09	10.921	3.7659 525.81	1.769	0.6100 85.171	3.294	1.1359 158.59
637824	277.00	1.873	0.6762	2.490	0.8989 132.94	9.473	3.4199 505.77	2.234	0.8065 119.27	3.178	1.1473 169.67
Mean	280.20	1.924	0.6868	2.668	0.9516 138.67	9.851	3.5095 511.66	2.010	0.7166 104.81	3.281	1.1727 170.82
S.D.	10.40	0.093	0.0304	0.199	0.0476 7.2241	1.023	0.2496 40.345	0.338	0.1109 18.989	0.092	0.0646 7.5735

Group : VII - 600 mg/m³ Treatment : 600 mg/m³ VII Sex : MALES

ANIMAL	FINA (Gms)	BRAIN		KIDNEYS		LIVER		LUNGS		TESTES	
		(Gms)	%FINA	(Gms)	%FINA %BRAIN	(Gms)	%FINA %BRAIN	(Gms)	%FINA %BRAIN	(Gms)	%FINA %BRAIN
637830	264.00	1.793	0.6792	2.750	1.0417 153.37	9.650	3.6553 538.20	1.695	0.6420 94.534	2.584	0.9788 144.12
637831	270.00	1.868	0.6919	2.642	0.9785 141.43	9.616	3.5615 514.78	1.775	0.6574 95.021	3.165	1.1722 169.43
637832	283.00	1.980	0.6996	2.697	0.9530 136.21	11.220	3.9647 566.67	2.157	0.7622 108.94	2.901	1.0251 146.52
637833	290.00	1.955	0.6741	2.886	0.9952 147.62	9.905	3.4155 506.65	1.698	0.5855 86.854	3.381	1.1659 172.94
637834	275.00	1.934	0.7033	2.865	1.0418 148.14	9.768	3.5520 505.07	1.694	0.6160 87.590	2.821	1.0258 145.86
Mean	276.40	1.906	0.6896	2.768	1.0020 145.36	10.032	3.6298 526.27	1.804	0.6526 94.588	2.970	1.0736 155.77
S.D.	10.31	0.076	0.0127	0.106	0.0392 6.6362	0.674	0.2058 26.177	0.200	0.0671 8.8731	0.309	0.0893 14.152

Individual Animal Final Body and Organ Weights

Group : I - 0 mg/m³ Treatment : 0 mg/m³ I Sex : MALES

ANIMAL	FINA (Gms)	BRAIN (Gms)	%FINA	KIDNEYS (Gms)	%FINA	%BRAIN	LIVER (Gms)	%FINA	%BRAIN	LUNGS (Gms)	%FINA	%BRAIN	TESTES (Gms)	%FINA	%BRAIN
637805	388.50	2.007	0.5166	3.224	0.8299	160.64	12.558	3.2324	625.71	1.906	0.4906	94.968	3.177	0.8178	158.30
637806	393.60	2.087	0.5302	3.452	0.8770	165.40	12.921	3.2828	619.12	1.759	0.4469	84.284	3.378	0.8582	161.86
637807	320.60	1.982	0.6182	2.649	0.8263	133.65	9.789	3.0533	493.90	1.526	0.4760	76.993	2.632	0.8210	132.80
637808	438.50	1.983	0.4522	3.698	0.8433	186.49	13.255	3.0228	668.43	2.159	0.4924	108.88	3.287	0.7496	165.76
637809	337.80	1.669	0.4941	2.884	0.8538	172.80	10.553	3.1240	632.29	1.582	0.4683	94.787	3.392	1.0041	203.24
Mean	375.80	1.946	0.5223	3.181	0.8460	163.80	11.815	3.1431	607.89	1.786	0.4748	91.981	3.173	0.8501	164.39
S.D.	47.17	0.160	0.0612	0.422	0.0205	19.474	1.545	0.1122	66.519	0.257	0.0186	12.105	0.315	0.0946	25.262

Group : III - 25 mg/m³ Treatment : 25 mg/m³ III Sex : MALES

ANIMAL	FINA (Gms)	BRAIN (Gms)	%FINA	KIDNEYS (Gms)	%FINA	%BRAIN	LIVER (Gms)	%FINA	%BRAIN	LUNGS (Gms)	%FINA	%BRAIN	TESTES (Gms)	%FINA	%BRAIN
637815	332.40	1.894	0.5698	2.749	0.8270	145.14	9.229	2.7765	487.28	NW			2.998	0.9019	158.29
637816	370.00	2.115	0.5716	3.052	0.8249	144.30	13.003	3.5143	614.80	1.490	0.4027	70.449	3.596	0.9719	170.02
637817	296.20	1.947	0.6573	2.410	0.8136	123.78	8.944	3.0196	459.37	1.579	0.5331	81.099	2.856	0.9642	146.69
637818	357.40	1.931	0.5403	2.832	0.7924	146.66	10.014	2.8019	518.59	1.910	0.5344	98.912	3.577	1.0008	185.24
637819	388.50	2.152	0.5539	3.335	0.8584	154.97	12.945	3.3320	601.53	1.809	0.4656	84.061	3.439	0.8852	159.80
Mean	348.90	2.008	0.5786	2.876	0.8233	142.97	10.827	3.0889	536.31	1.697	0.4840	83.631	3.293	0.9448	164.01
S.D.	35.83	0.117	0.0458	0.345	0.0240	11.537	1.999	0.3259	69.015	0.196	0.0630	11.746	0.343	0.0491	14.469

NW = NOT WEIGHED

H-24267: Two-Week Inhalation Toxicity Study in Male Rats

DuPont-4292

Individual Animal Final Body and Organ Weights

Group : V - 125 mg/m³ Treatment : 125 mg/m³ V Sex : MALES

ANIMAL	FINA		BRAIN		KIDNEYS		LIVER		LUNGS		TESTES	
	(Gms)		(Gms)	%FINA	(Gms)	%FINA	(Gms)	%FINA	(Gms)	%FINA	(Gms)	%FINA
637825	364.90		2.215	0.6070	3.246	0.8896	146.55	11.459	3.1403	517.34	1.682	0.4609
637826	405.40		2.058	0.5076	3.726	0.9191	181.05	13.358	3.2950	649.08	2.040	0.5032
637827	349.20		1.916	0.5487	3.094	0.8860	161.48	11.643	3.3342	607.67	1.986	0.5687
637828	385.90		2.102	0.5447	3.376	0.8748	160.61	12.835	3.3260	610.61	1.764	0.4571
637829	391.20		2.038	0.5210	3.169	0.8101	155.50	13.510	3.4535	662.90	1.889	0.4829
Mean	379.32		2.066	0.5458	3.322	0.8759	161.04	12.561	3.3098	609.52	1.872	0.4946
S.D.	22.25		0.108	0.0382	0.249	0.0403	12.665	0.958	0.1123	56.827	0.149	0.0454

Group : VII - 600 mg/m³ Treatment : 600 mg/m³ VII Sex : MALES

ANIMAL	FINA		BRAIN		KIDNEYS		LIVER		LUNGS		TESTES	
	(Gms)		(Gms)	%FINA	(Gms)	%FINA	(Gms)	%FINA	(Gms)	%FINA	(Gms)	%FINA
637835	345.50		2.042	0.5910	3.318	0.9603	162.49	12.712	3.6793	622.53	1.834	0.5308
637836	384.60		1.968	0.5117	3.029	0.7876	153.91	12.175	3.1656	618.65	2.142	0.5569
637837	291.10		1.816	0.6238	2.555	0.8777	140.69	8.896	3.0560	489.87	1.466	0.5036
637838	413.80		2.068	0.4998	3.717	0.8983	179.74	14.462	3.4949	699.32	2.210	0.5341
637839	335.00		2.057	0.6140	3.316	0.9899	161.21	11.120	3.3194	540.59	1.916	0.5719
Mean	354.00		1.990	0.5681	3.187	0.9027	159.61	11.873	3.3431	594.19	1.914	0.5395
S.D.	47.18		0.105	0.0583	0.430	0.0788	14.198	2.057	0.2503	80.947	0.294	0.0262

APPENDIX G

Individual Animal Pathology Data

KEY TO APPENDIX

INDIVIDUAL ANIMAL PATHOLOGY DATA

LESION GRADING:

Histopathological changes are described according to their morphologic character, distribution and severity. The distribution (extent of tissue involvement) is indicated, where appropriate, by modifiers such as focal, multifocal, diffuse, unilateral, bilateral, etc. A severity score, if appropriate, is also assigned as follows:

- MINIMAL: the amount of change present barely exceeds that which is considered to be within normal limits.
- MILD: in general, the lesion is easily identified but of limited severity. the lesion probably does not produce any functional impairment.
- MODERATE: the lesion is prominent but there is significant potential for increased severity. limited tissue or organ dysfunction is possible.
- SEVERE: the degree of change is either as complete as considered possible or great enough in intensity or extent to expect significant tissue or organ dysfunction.

COMMENT:

Grades minimal through severe represent progressive involvement/severity along a continuum with minimal lesions being the least severe and severe lesions being the most severe. While the grades refer to the morphological characteristics of lesions, they also indicate their relative biological significance.

Gross observations listing multiple masses for a tissue are distinguished with letters (i.e., A, b, c, d, etc.).

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637800 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

ADRENAL GLANDS :

NOT PRESENT, MEDULLA.

TESTES :

DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL,
mild.

EPIDIDYMIDES :

OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL, mild.

No Microscopic Abnormality Observed :

LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, SCIATIC NERVE,
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS,
PHARYNX/LARYNX, EYE(S), PROSTATE, SEMINAL VESICLES,
URINARY BLADDER, STERNUM, BONE MARROW, NOSE I & II, NOSE
III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637801	Terminal Sacrifice Killed on Day : 11 Exposure Group : MAIN Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

PROSTATE :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :

KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC
NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), SEMINAL VESICLES,
URINARY BLADDER, TESTES, EPIDIDYMIDES, STERNUM,
BONE MARROW, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637802 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYIMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :

KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC
NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYIMIDES,
STERNUM, BONE MARROW, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637803 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

EPIDIDYMIDES :

DISCOLORATION, MOTTLED, TAIL, RIGHT, 3MM dia.

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

LUNGS :

INFLAMMATION, SUBACUTE/CHRONIC, FOCAL, minimal.

PARATHYROID GLANDS :

NOT PRESENT.

EPIDIDYMIDES :

GRANULOMA, SPERM.

No Microscopic Abnormality Observed :

KIDNEYS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC
NERVE, THYROID GLAND, TRACHEA, ESOPHAGUS, PHARYNX/LARYNX,
EYE(S), PROSTATE, SEMINAL VESICLES, URINARY BLADDER,
TESTES, STERNUM, BONE MARROW, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637804 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

LIVER :

DISCOLORATION, YELLOW, LEFT, 4 MM dia.
DEFORMITY, IRREGULAR, MIDDLE, only one lobe evident.

No Macroscopic Abnormality Observed :

KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC
NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYIMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.
INFLAMMATION, GRANULOMATOUS, minimal, with mineralization.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

ADRENAL GLANDS :

NOT PRESENT, MEDULLA.

TESTES :

DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL,
mild.

EPIDIDYIMIDES :

OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL, minimal.

No Microscopic Abnormality Observed :

LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, SCIATIC NERVE,
THYROID GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS,
PHARYNX/LARYNX, EYE(S), PROSTATE, SEMINAL VESICLES,
URINARY BLADDER, STERNUM, BONE MARROW, NOSE I & II, NOSE
III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637805 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637806 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637807 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

TESTES :

DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, UNILATERAL,
minimal.

No Microscopic Abnormality Observed :

KIDNEYS, LUNGS, PHARYNX/LARYNX, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637808	Terminal Sacrifice Killed on Day : 25 Exposure Group : RECOVERY Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, mild.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

LUNGS :

INFLAMMATION, SUBACUTE/CHRONIC, FOCAL, minimal.

No Microscopic Abnormality Observed :

PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : I - 0 mg/m³ Treatment: 0 mg/m³ I Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637809 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637810	Terminal Sacrifice Killed on Day : 11 Exposure Group : MAIN Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
LUNGS :
INFLAMMATION, SUBACUTE/CHRONIC, FOCAL, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.
INFLAMMATION, ACUTE, PERIVASCULAR, minimal.
NOSE III & IV :
HYPERTROPHY, GOBLET CELL, minimal.
No Microscopic Abnormality Observed :
KIDNEYS, PHARYNX/LARYNX, TESTES, NOSE I & II

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637811 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :
 INFLAMMATION, SUBACUTE/CHRONIC, minimal.
LUNGS :
 INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.
 INFLAMMATION, ACUTE, PERIVASCULAR, minimal.
NOSE III & IV :
 HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :
KIDNEYS, PHARYNX/LARYNX, TESTES, NOSE I & II

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637812 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

LUNGS :

INFLAMMATION, SUBACUTE/CHRONIC, FOCAL, minimal.

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

No Microscopic Abnormality Observed :

KIDNEYS, PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637813 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMITES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

PHARYNX/LARYNX :

METAPLASIA, SQUAMOUS, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

KIDNEYS, LUNGS, TESTES, NOSE I & II

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637814 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

KIDNEYS :
 DILATATION, UNILATERAL, PELVIS, mild.
SPLEEN :
 DEFORMITY, IRREGULAR.

No Macroscopic Abnormality Observed :
LIVER, LUNGS, HEART, BRAIN, SPINAL CORD, STOMACH, DUODENUM,
JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC
LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID
GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS,
PHARYNX/LARYNX, EYE(S), PROSTATE, SEMINAL VESICLES,
URINARY BLADDER, TESTES, EPIDIDYMIDES, STERNUM, NOSE

Histopathology :

LIVER :
 INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
 HYDRONEPHROSIS, UNILATERAL, minimal.
PHARYNX/LARYNX :
 METAPLASIA, SQUAMOUS, minimal.
NOSE III & IV :
 HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :
LUNGS, SPLEEN, TESTES, NOSE I & II

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637815	Terminal Sacrifice Killed on Day : 25 Exposure Group : RECOVERY Animal is signed off from necropsy
--------	---

Gross Pathology :

LUNGS :

Inflated, not weighed, protocol deviation.

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC
NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637816 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637817 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637818 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : III - 25 mg/m³ Treatment: 25 mg/m³ III Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637819 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637820 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

LUNGS :

HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

PHARYNX/LARYNX :

METAPLASIA, SQUAMOUS, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

TESTES, NOSE I & II

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637821 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

LUNGS :

HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

PHARYNX/LARYNX :

METAPLASIA, SQUAMOUS, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

TESTES, NOSE I & II

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637822 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMITES,
STERNUM, NOSE

Histopathology :

LIVER :
 INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
 NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.
LUNGS :
 HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.
 INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.
PHARYNX/LARYNX :
 METAPLASIA, SQUAMOUS, minimal.

No Microscopic Abnormality Observed :
 TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637823	Terminal Sacrifice Killed on Day : 11 Exposure Group : MAIN Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.

LUNGS :

HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

PHARYNX/LARYNX :

METAPLASIA, SQUAMOUS, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

KIDNEYS, TESTES, NOSE I & II

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637824	Terminal Sacrifice Killed on Day : 11 Exposure Group : MAIN Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

LUNGS :

HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

PHARYNX/LARYNX, TESTES, NOSE I & II

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637825	Terminal Sacrifice Killed on Day : 25 Exposure Group : RECOVERY Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :
LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637826 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LUNGS :

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

No Microscopic Abnormality Observed :

PHARYNX/LARYNX

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637827 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637828 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LUNGS :
INFLAMMATION, SUBACUTE/CHRONIC, FOCAL, minimal.

No Microscopic Abnormality Observed :
PHARYNX/LARYNX

Individual Animal Listing

Dose Group : V - 125 mg/m³ Treatment: 125 mg/m³ V Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637829	Terminal Sacrifice Killed on Day : 25 Exposure Group : RECOVERY Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637830 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :
 INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
 NEPHROPATHY, CHRONIC PROGRESSIVE, mild.
LUNGS :
 HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.
 INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.
PHARYNX/LARYNX :
 METAPLASIA, SQUAMOUS, minimal.
TESTES :
 DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL,
 mild.
EPIDIDYMIDES :
 OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL, minimal.
NOSE III & IV :
 HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :
HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH, DUODENUM,
JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC
LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID
GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, EYE(S),
PROSTATE, SEMINAL VESICLES, URINARY BLADDER, STERNUM,
BONE MARROW, NOSE I & II

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637831 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYIMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

LUNGS :

HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

PHARYNX/LARYNX :

METAPLASIA, SQUAMOUS, minimal.

NOSE I & II :

HYPERTROPHY, GOBLET CELL, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

KIDNEYS, HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH,
DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM,
MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC
NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, EYE(S), PROSTATE, SEMINAL VESICLES,
URINARY BLADDER, TESTES, EPIDIDYIMIDES, STERNUM, BONE MARROW

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637832 Terminal Sacrifice
 Killed on Day : 11
 Exposure Group : MAIN
 Animal is signed off from necropsy

Gross Pathology :

EPIDIDYMIDES :
DISCOLORATION, TAN, FIRM, TAIL.

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, STERNUM, NOSE

Histopathology :

LIVER :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.
LUNGS :
HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.
INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.
PHARYNX/LARYNX :
NECROSIS, CARTILAGE, minimal.
EPIDIDYMIDES :
OLIGOSPERMIA/GERM CELL DEBRIS, UNILATERAL, minimal.
NOSE I & II :
INFLAMMATION, SUBACUTE/CHRONIC, minimal.
HYPERPLASIA/HYPERTROPHY, RESPIRATORY, minimal.
NOSE III & IV :
HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :
HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH, DUODENUM,
JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC
LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID
GLAND, PARATHYROID GLANDS, TRACHEA, ESOPHAGUS, EYE(S),
PROSTATE, SEMINAL VESICLES, URINARY BLADDER, TESTES,
STERNUM, BONE MARROW

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637833	Terminal Sacrifice Killed on Day : 11 Exposure Group : MAIN Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

LUNGS :

HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

PARATHYROID GLANDS :

NOT PRESENT.

PHARYNX/LARYNX :

METAPLASIA, SQUAMOUS, minimal.

TESTES :

DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL,
minimal.

EPIDIDYMIDES :

OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL, minimal.

NOSE I & II :

DEGENERATION/NECROSIS, OLFACTORY, minimal.

HYPERPLASIA/HYPERTROPHY, RESPIRATORY, minimal.

HYPERTROPHY, GOBLET CELL, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH, DUODENUM,
JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC
LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID
GLAND, TRACHEA, ESOPHAGUS, EYE(S), PROSTATE, SEMINAL
VESICLES, URINARY BLADDER, STERNUM, BONE MARROW

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637834	Terminal Sacrifice Killed on Day : 11 Exposure Group : MAIN Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

LUNGS :

HYPERTROPHY, BRONCHIOLAR EPITHELIAL CELL, minimal.

INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

PARATHYROID GLANDS :

NOT PRESENT.

PHARYNX/LARYNX :

METAPLASIA, SQUAMOUS, minimal.

TESTES :

DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL,
minimal.

EPIDIDYMIDES :

OLIGOSPERMIA/GERM CELL DEBRIS, BILATERAL, minimal.

NOSE III & IV :

HYPERTROPHY, GOBLET CELL, minimal.

No Microscopic Abnormality Observed :

HEART, SPLEEN, BRAIN, SPINAL CORD, STOMACH, DUODENUM,
JEJUNUM, ILEUM, PANCREAS, CECUM, COLON, RECTUM, MESENTERIC
LYMPH NODE, THYMUS, ADRENAL GLANDS, SCIATIC NERVE, THYROID
GLAND, TRACHEA, ESOPHAGUS, EYE(S), PROSTATE, SEMINAL
VESICLES, URINARY BLADDER, STERNUM, BONE MARROW,
NOSE I & II

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637835	Terminal Sacrifice Killed on Day : 25 Exposure Group : RECOVERY Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

No Microscopic Abnormality Observed :

LUNGS, PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637836 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :
 INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
 NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.
PHARYNX/LARYNX :
 NECROSIS, CARTILAGE, minimal.

No Microscopic Abnormality Observed :
LUNGS, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637837 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYIMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.
FATTY CHANGE, MEDIAN CLEFT, minimal.

KIDNEYS :

NEPHROPATHY, CHRONIC PROGRESSIVE, minimal.

PHARYNX/LARYNX :

NECROSIS, CARTILAGE, minimal.

No Microscopic Abnormality Observed :

LUNGS, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref Microscopic & Macroscopic Findings

637838 Terminal Sacrifice
 Killed on Day : 25
 Exposure Group : RECOVERY
 Animal is signed off from necropsy

Gross Pathology :

No Macroscopic Abnormality Observed :
LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYIMIDES,
STERNUM, NOSE

Histopathology :

LIVER :
 INFLAMMATION, SUBACUTE/CHRONIC, minimal.
KIDNEYS :
 HYDRONEPHROSIS, UNILATERAL, minimal.
LUNGS :
 INFLAMMATION, SUBACUTE/CHRONIC, CENTRIACINAR, minimal.

No Microscopic Abnormality Observed :
PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE III & IV

Individual Animal Listing

Dose Group : VII - 600 mg/m³ Treatment: 600 mg/m³ VII Sex: Males

Animal Ref	Microscopic & Macroscopic Findings
------------	------------------------------------

637839	Terminal Sacrifice Killed on Day : 25 Exposure Group : RECOVERY Animal is signed off from necropsy
--------	---

Gross Pathology :

No Macroscopic Abnormality Observed :

LIVER, KIDNEYS, LUNGS, HEART, SPLEEN, BRAIN, SPINAL CORD,
STOMACH, DUODENUM, JEJUNUM, ILEUM, PANCREAS, CECUM, COLON,
RECTUM, MESENTERIC LYMPH NODE, THYMUS, ADRENAL GLANDS,
SCIATIC NERVE, THYROID GLAND, PARATHYROID GLANDS, TRACHEA,
ESOPHAGUS, PHARYNX/LARYNX, EYE(S), PROSTATE,
SEMINAL VESICLES, URINARY BLADDER, TESTES, EPIDIDYMIDES,
STERNUM, NOSE

Histopathology :

LIVER :

INFLAMMATION, SUBACUTE/CHRONIC, minimal.

No Microscopic Abnormality Observed :

KIDNEYS, LUNGS, PHARYNX/LARYNX, TESTES, NOSE I & II, NOSE
III & IV